Page last updated: 2024-11-13

raltegravir

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID54671008
CHEMBL ID254316
CHEBI ID82960
SCHEMBL ID51817
SCHEMBL ID2112870
SCHEMBL ID996804
MeSH IDM0508784

Synonyms (93)

Synonym
raltegravir ,
518048-05-0
mk-0518
D06676
raltegravir (inn)
n-[2-(4-{[(4-fluorophenyl)methyl]carbamoyl}-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide
bdbm25351
RLT ,
n-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(1-methyl-1-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}ethyl)-6-oxo-1,6-di hydropyrimidine-4-carboxamide
CHEMBL254316
n-(2-(4-(4-fluorobenzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1, 6-dihydropyrimidin-2-yl)propan-2-yl) -5-methyl-1,3,4-oxadiazole-2- carboxamide
isentress(tm)
k-0518 ,
A25486
mk-0518;n-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo-4-pyrimidinecarboxamide potassium salt
NCGC00184997-01
raltegravir [usan:inn]
unii-22vkv8053u
mk0518
hsdb 8124
22vkv8053u ,
4-pyrimidinecarboxamide, n-((4-fluorophenyl)methyl)-1,6-dihydro-5-hydroxy-1-methyl-2-(1-methyl-1-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)ethyl)-6-oxo-
n-(2-(4-(4-fluorobenzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide
mk 0518
dtxsid2048660 ,
dtxcid5028586
tox21_113019
cas-518048-05-0
A828788
(z)-n-(2-(4-(((4-fluorophenyl)(methyl)amino)(hydroxy)methylene)-1-methyl-5,6-dioxo-1,4,5,6-tetrahydropyrimidin-2-yl)propan-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide
raltegravir (mk-0518)
BCPP000093
FT-0649660
[(5-methyl-1,3,4-oxadiazol-2-yl)formamido]propan-2-
n-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-2-{2-
yl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide
PB13312
raltegravir [ema epar]
n-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(1-methyl-1-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)ethyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide
raltegravir [inn]
raltegravir [who-dd]
n-(2-(4-(4-fluorobenzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6- dihydropyrimidin-2-yl)propan-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide
raltegravir [mart.]
raltegravir [mi]
raltegravir [vandf]
S2005
AKOS015902444
BRD-K05658747-237-01-1
DB06817
HY-10353
CZFFBEXEKNGXKS-UHFFFAOYSA-N
SCHEMBL51817
MLS006011985
smr003601806
tox21_113019_1
NCGC00274066-01
SCHEMBL2112870
SCHEMBL996804
AKOS025149884
n-(2-(4-((4-fluorobenzyl)carbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide
AB01566833_01
n-(2-(4-(4-fluorobenzylcarbamoyl)-5-oh-1-me-6-oxo-pyrimidin-2-yl)propan-2-yl)-5-me-1,3,4-oxadiazole-2-carboxamide
mfcd10698872
AC-5261
HMS3655B09
NCGC00274066-05
n-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-2-{2-[(5-methyl-1,3,4-oxadiazol-2-yl)formamido]propan-2-yl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide
SW220138-1
hydropyrimidine-4-carboxamide
n-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(1-methyl-1-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}ethyl)-6-oxo-1,6-di
AKOS032960305
Q421552
518048-05-0 (free)
Z1532717445
EX-A2147
raltegravir; mk-0518
AS-16992
BCP01394
SB20935
n-[2-[4-[(4-fluorophenyl)methylcarbamoyl]-5-hydroxy-1-methyl-6-oxopyrimidin-2-yl]propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide
CCG-269170
nsc-762522
nsc762522
n-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(2-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}propan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide
CHEBI:82960 ,
raltegravirum
gtpl11571
EN300-120882
raltegravir- bio-x
BR164312
raltegravir (mart.)
n-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(2-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)propan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide
j05ax08

Research Excerpts

Overview

Raltegravir is a novel human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor with potent in vitro activity against HIV-1. The drug is metabolized by glucuronidation via UGT1A1 and may be affected by inducers, such as rifampin (rifampicin)

ExcerptReferenceRelevance
"Raltegravir is a novel human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor with potent in vitro activity against HIV-1 (95% inhibitory concentration = 31 nM in 50% human serum). "( Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
Azrolan, N; Breidinger, SA; De Smet, M; Gottesdiener, KM; Greenberg, HE; Haazen, W; Iwamoto, M; Kost, JT; Laethem, M; Mangin, EC; Petry, AS; Stone, JA; Wagner, JA; Wenning, LA, 2008
)
2.02
"Raltegravir is a human immunodeficiency virus type 1 integrase strand transfer inhibitor with potent activity in vitro and in vivo. "( Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
Breidinger, SA; Friedman, EJ; Hanley, WD; Iwamoto, M; Kost, JT; Lasseter, KC; Lunde, NM; Petry, AS; Robson, R; Stone, JA; Wagner, JA; Wenning, LA, 2009
)
2.01
"Raltegravir is a human immunodeficiency virus type 1 integrase strand transfer inhibitor that is metabolized by glucuronidation via UGT1A1 and may be affected by inducers of UGT1A1, such as rifampin (rifampicin). "( Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
Berg, JK; Brainard, DM; Chodakewitz, JA; Ghosh, K; Gottesdiener, KM; Hanley, WD; Iwamoto, M; Jin, B; Mangin, E; Marbury, TC; Petry, AS; Stone, JA; Wagner, JA; Wenning, LA, 2009
)
2.01

Pharmacokinetics

ExcerptReferenceRelevance
" Two pharmacokinetic studies were performed in healthy subjects: study 1 examined the effect of administration of 600-mg rifampin once daily on the pharmacokinetics of a single dose of 400-mg raltegravir, and study 2 examined the effect of 600-mg rifampin once daily on the pharmacokinetics of 800-mg raltegravir twice daily compared to 400-mg raltegravir twice daily without rifampin."( Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
Berg, JK; Brainard, DM; Chodakewitz, JA; Ghosh, K; Gottesdiener, KM; Hanley, WD; Iwamoto, M; Jin, B; Mangin, E; Marbury, TC; Petry, AS; Stone, JA; Wagner, JA; Wenning, LA, 2009
)
0.76
" Subjects underwent two intensive pharmacokinetic visits in the fasted state separated by a 5- to 12-day washout period."( Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
Anderson, PL; Brundage, R; Bumpass, JB; Bushman, L; Kiser, JJ; Mawhinney, S; Meditz, AL; Predhomme, JA; Ray, M; Rower, J, 2010
)
0.62
" On day 10, a full pharmacokinetic profile was obtained for each participant."( Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.
Back, D; Barbanoj, MJ; Cedeño, S; Clotet, B; Egan, D; Liptrott, N; Miranda, C; Moltó, J; Valle, M; Watson, V, 2011
)
0.59
"This work is a continuation of our initial discovery of a potent monocyclic carbamoyl pyridone human immunodeficiency virus type-1 (HIV-1) integrase inhibitor that displayed favorable antiviral and pharmacokinetic properties."( Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles.
Akiyama, T; Fuji, M; Fujiwara, T; Garvey, EP; Johns, BA; Kawasuji, T; Kiyama, R; Kobayashi, M; Mikamiyama-Iwata, M; Murai, H; Sato, A; Seki, T; Taishi, T; Tanimoto, N; Taoda, Y; Weatherhead, JG; Yoshida, H; Yoshinaga, T, 2013
)
0.39

Bioavailability

ExcerptReferenceRelevance
" A highly potent and orally bioavailable compound (compound 9) was identified and selected for development."( Tricyclic HIV integrase inhibitors: potent and orally bioavailable C5-aza analogs.
Cai, R; Chen, X; Jabri, S; Jin, H; Kim, CU; Lansdown, R; Metobo, S; Mish, M; Pastor, R; Pyun, P; Tsiang, M; Wright, M, 2008
)
0.35
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The primary outcome was the ratio of plasma raltegravir C(tau), or concentration at the end of the dosing interval, for arm B (24 h) versus arm A (12 h) Studies are needed to determine the clinical relevance of this interaction.

ExcerptRelevanceReference
" The pharmacokinetic profile of GS-9160 in healthy human volunteers revealed that once-daily dosing was not likely to achieve antiviral efficacy; hence, the clinical development of this compound was discontinued."( Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
Chen, J; Chen, X; Geleziunas, R; Hesselgesser, J; Jin, H; Jones, GS; Kim, CU; Tsiang, M; Wright, M; Yu, F; Zeynalzadegan, A, 2009
)
0.35
" The primary outcome was the ratio of plasma raltegravir C(tau), or concentration at the end of the dosing interval, for arm B (24 h) versus arm A (12 h)."( Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
Calmy, A; Decosterd, L; di Iulio, J; Fayet, A; Jelliffe, R; Kanani, M; Lee, JS; Margol, A; Neely, M; von Schoen-Angerer, T, 2010
)
0.87
" Studies are needed to determine the clinical relevance of this interaction, whether it remains after multiple dosing to steady state, whether it is mitigated by temporal separation, and whether raltegravir interacts with divalent cation-containing vitamins, supplements, or foods."( Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
Anderson, PL; Brundage, R; Bumpass, JB; Bushman, L; Kiser, JJ; Mawhinney, S; Meditz, AL; Predhomme, JA; Ray, M; Rower, J, 2010
)
0.81
" The geometric mean raltegravir maximum concentration, the concentration at the end of the dosing interval, and the area under the concentration-time curve during the dose interval in plasma versus PBMCs were 2,640 ng/ml (range, 887 to 10,605 ng/ml) versus 199 ng/ml (range, 82 to 857 ng/ml) (geometric mean ratio [GMR], 13."( Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.
Back, D; Barbanoj, MJ; Cedeño, S; Clotet, B; Egan, D; Liptrott, N; Miranda, C; Moltó, J; Valle, M; Watson, V, 2011
)
0.91
" The new inhibitor design displayed a remarkable PK profile suggestive of once daily dosing without the need for a PK booster as demonstrated by robust drug concentrations at 24 h after oral dosing in rats, dogs, and cynomolgus monkeys."( Carbamoyl pyridone HIV-1 integrase inhibitors. 1. Molecular design and establishment of an advanced two-metal binding pharmacophore.
Fuji, M; Fujiwara, T; Johns, BA; Kawasuji, T; Kiyama, R; Kobayashi, M; Murai, H; Sato, A; Seki, T; Taishi, T; Taoda, Y; Yoshida, H; Yoshinaga, T, 2012
)
0.38
" Additionally, we observe additive inhibitory activity against pseudotyped viruses when B#24 is dosed in competition with the clinically used non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz."( Biological evaluation of molecules of the azaBINOL class as antiviral agents: Inhibition of HIV-1 RNase H activity by 7-isopropoxy-8-(naphth-1-yl)quinoline.
Banerjee, S; Blakemore, PR; Brack-Werner, R; Herrmann, A; Loesgen, S; Milicevic Sephton, S; Neuhaus, GF; Overacker, RD; Strother, JA, 2019
)
0.51
" The available treatments are hampered by issues such as toxicity, variable efficacy, and unsuitable dosing options."( Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent
De Rycker, M; Epemolu, O; Fiandor, JM; Gilbert, IH; Manthri, S; Marco, M; Miles, TJ; Naylor, C; Norval, S; Osuna-Cabello, M; Patterson, S; Read, KD; Riley, J; Simeons, FRC; Spinks, D; Stojanovski, L; Thomas, J; Thomas, MG; Thompson, S; Wall, RJ; Wyatt, PG; Wyllie, S, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antiviral drugA substance used in the prophylaxis or therapy of virus diseases.
HIV-1 integrase inhibitorAn inhibitor of HIV-1 integrase, an enzyme required for the integration of the genetic material of the retrovirus into the DNA of the infected cells.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
1,2,4-oxadiazole
dicarboxylic acid amide
monofluorobenzenesAny member of the class of fluorobenzenes containing a mono- or poly-substituted benzene ring carrying a single fluorine substitutent.
pyrimidoneA pyrimidine carrying one or more oxo substituents.
hydroxypyrimidine
secondary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (26)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency19.98260.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency10.68220.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency10.68220.173734.304761.8120AID1346859
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency0.06170.01237.983543.2770AID1645841
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency32.27740.003041.611522,387.1992AID1159552; AID1159553; AID1159555
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency23.70830.001024.504861.6448AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency29.84700.001019.414170.9645AID743191
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)IC50 (µMol)246.70000.00032.63119.0000AID1207765
Gag-Pol polyproteinHIV-1 M:B_HXB2RIC50 (µMol)0.01500.00060.91418.3200AID1798545
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)50.00000.00011.774010.0000AID364185
DNA polymerase betaHomo sapiens (human)IC50 (µMol)50.00001.40006.56679.0000AID364183
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)50.00000.00011.753610.0000AID364188
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)50.00000.00002.015110.0000AID364187
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)50.00000.00002.800510.0000AID364186
Potassium voltage-gated channel subfamily E member 1Homo sapiens (human)IC50 (µMol)25.11890.12004.048010.0000AID1207382
UDP-glucuronosyltransferase 1A1 Homo sapiens (human)IC50 (µMol)180.00000.30003.25807.3000AID1222388; AID1222389
C-C chemokine receptor type 1Homo sapiens (human)Ki0.00500.00100.03300.0740AID707909
Potassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)IC50 (µMol)25.11890.12004.048010.0000AID1207382
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)IC50 (µMol)246.70000.00032.59559.0000AID1207765
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)1,278.34950.00091.901410.0000AID1207476; AID1207505; AID1207536; AID364189
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)IC50 (µMol)246.70000.00032.63119.0000AID1207765
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)IC50 (µMol)246.70000.00032.25459.6000AID1207765
Sodium channel protein type 5 subunit alphaHomo sapiens (human)IC50 (µMol)950.55900.00033.64849.2000AID1207322; AID1207351
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)40.00000.00011.076810.0000AID1126725; AID1228824; AID1406290; AID1503544; AID1602241; AID1635810
Integrase Human immunodeficiency virus 1IC50 (µMol)2.66980.00051.544310.0000AID1053411; AID1060851; AID1126722; AID1126723; AID1152120; AID1191594; AID1199594; AID1228821; AID1228822; AID1237269; AID1237270; AID1261364; AID1264512; AID1264513; AID1361065; AID1406292; AID1503546; AID1552564; AID1565222; AID1565224; AID1588917; AID1588920; AID1602243; AID1635801; AID1655467; AID1847041; AID1907129; AID331697; AID331698; AID364176; AID375392; AID375393; AID413246; AID413252; AID413253; AID434440; AID497131; AID497132; AID519018; AID519038; AID541108; AID569000; AID573970; AID573971; AID595928; AID595929; AID595930; AID595931; AID596553; AID612820; AID634130; AID760005; AID760006; AID760007
Potassium voltage-gated channel subfamily D member 3Homo sapiens (human)IC50 (µMol)5,011.87011.40005.35009.3000AID1207442
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Integrase Human immunodeficiency virus 1C500.00700.00700.05400.1400AID569001
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (232)

Processvia Protein(s)Taxonomy
visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
detection of light stimulus involved in visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
viral life cycleGag-Pol polyproteinHIV-1 M:B_HXB2R
establishment of integrated proviral latencyGag-Pol polyproteinHIV-1 M:B_HXB2R
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
nucleotide-excision repair, DNA gap fillingDNA polymerase betaHomo sapiens (human)
in utero embryonic developmentDNA polymerase betaHomo sapiens (human)
DNA-templated DNA replicationDNA polymerase betaHomo sapiens (human)
DNA repairDNA polymerase betaHomo sapiens (human)
base-excision repairDNA polymerase betaHomo sapiens (human)
base-excision repair, gap-fillingDNA polymerase betaHomo sapiens (human)
pyrimidine dimer repairDNA polymerase betaHomo sapiens (human)
inflammatory responseDNA polymerase betaHomo sapiens (human)
DNA damage responseDNA polymerase betaHomo sapiens (human)
salivary gland morphogenesisDNA polymerase betaHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageDNA polymerase betaHomo sapiens (human)
response to gamma radiationDNA polymerase betaHomo sapiens (human)
somatic hypermutation of immunoglobulin genesDNA polymerase betaHomo sapiens (human)
response to ethanolDNA polymerase betaHomo sapiens (human)
lymph node developmentDNA polymerase betaHomo sapiens (human)
spleen developmentDNA polymerase betaHomo sapiens (human)
homeostasis of number of cellsDNA polymerase betaHomo sapiens (human)
neuron apoptotic processDNA polymerase betaHomo sapiens (human)
response to hyperoxiaDNA polymerase betaHomo sapiens (human)
immunoglobulin heavy chain V-D-J recombinationDNA polymerase betaHomo sapiens (human)
DNA biosynthetic processDNA polymerase betaHomo sapiens (human)
double-strand break repair via nonhomologous end joiningDNA polymerase betaHomo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
epithelial cell maturationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
sensory perception of soundPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
male gonad developmentPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
vestibular nucleus developmentPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
secretory granule organizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cellular response to cAMPPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cellular response to acidic pHPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cellular response to light stimulusPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cardiac muscle cell action potential involved in contractionPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cardiac muscle cell contractionPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
negative regulation of protein targeting to membranePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
regulation of delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
negative regulation of delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
liver developmentUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
bilirubin conjugationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
acute-phase responseUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to nutrientUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
steroid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
animal organ regenerationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to lipopolysaccharideUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
retinoic acid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to starvationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
negative regulation of steroid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
flavone metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
flavonoid glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
xenobiotic glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
biphenyl catabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to ethanolUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to glucocorticoid stimulusUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to estradiol stimulusUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
dendritic cell chemotaxisC-C chemokine receptor type 1Homo sapiens (human)
monocyte chemotaxisC-C chemokine receptor type 1Homo sapiens (human)
calcium ion transportC-C chemokine receptor type 1Homo sapiens (human)
intracellular calcium ion homeostasisC-C chemokine receptor type 1Homo sapiens (human)
exocytosisC-C chemokine receptor type 1Homo sapiens (human)
chemotaxisC-C chemokine receptor type 1Homo sapiens (human)
immune responseC-C chemokine receptor type 1Homo sapiens (human)
cell adhesionC-C chemokine receptor type 1Homo sapiens (human)
cell surface receptor signaling pathwayC-C chemokine receptor type 1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationC-C chemokine receptor type 1Homo sapiens (human)
cell-cell signalingC-C chemokine receptor type 1Homo sapiens (human)
response to woundingC-C chemokine receptor type 1Homo sapiens (human)
negative regulation of gene expressionC-C chemokine receptor type 1Homo sapiens (human)
cytokine-mediated signaling pathwayC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of cell migrationC-C chemokine receptor type 1Homo sapiens (human)
negative regulation of bone mineralizationC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of osteoclast differentiationC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of calcium ion transportC-C chemokine receptor type 1Homo sapiens (human)
chemokine-mediated signaling pathwayC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeC-C chemokine receptor type 1Homo sapiens (human)
positive regulation of monocyte chemotaxisC-C chemokine receptor type 1Homo sapiens (human)
calcium-mediated signalingC-C chemokine receptor type 1Homo sapiens (human)
cell chemotaxisC-C chemokine receptor type 1Homo sapiens (human)
inflammatory responseC-C chemokine receptor type 1Homo sapiens (human)
gastrin-induced gastric acid secretionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
glucose metabolic processPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
heart developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
sensory perception of soundPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
rhythmic behaviorPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of heart contractionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of blood pressurePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
positive regulation of heart ratePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
iodide transportPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
erythrocyte differentiationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
intracellular chloride ion homeostasisPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
response to insulinPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
social behaviorPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
corticosterone secretionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
inner ear morphogenesisPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
inner ear developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
intestinal absorptionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of soundPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
auditory receptor cell developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
positive regulation of cardiac muscle contractionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of gastric acid secretionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
stomach developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
renal absorptionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
renal sodium ion absorptionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cellular response to cAMPPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cellular response to epinephrine stimulusPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
adrenergic receptor signaling pathwayPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cardiac muscle cell contractionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
atrial cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cochlea developmentPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane repolarization during atrial cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
non-motile cilium assemblyPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
action potentialPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
sensory perception of soundVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion importVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transporter activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
skeletal system developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
extraocular skeletal muscle developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
striated muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
endoplasmic reticulum organizationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
myoblast fusionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
neuromuscular junction developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle adaptationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle fiber developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
release of sequestered calcium ion into cytosolVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cellular response to caffeineVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
immune system developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
heart developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
embryonic forelimb morphogenesisVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
camera-type eye developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transport into cytosolVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of ventricular cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rateSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac conduction system developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac ventricle developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
brainstem developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
response to denervation involved in regulation of muscle adaptationSodium channel protein type 5 subunit alphaHomo sapiens (human)
telencephalon developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cerebellum developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
odontogenesis of dentin-containing toothSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of epithelial cell proliferationSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cellular response to calcium ionSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of cardiac muscle cell contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
ventricular cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during Purkinje myocyte cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell to bundle of His cell communicationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of heart rate by cardiac conductionSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
potassium ion transportPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
protein homooligomerizationPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
action potentialPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (96)

Processvia Protein(s)Taxonomy
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
peptidase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
integrase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
damaged DNA bindingDNA polymerase betaHomo sapiens (human)
DNA-directed DNA polymerase activityDNA polymerase betaHomo sapiens (human)
DNA-(apurinic or apyrimidinic site) endonuclease activityDNA polymerase betaHomo sapiens (human)
protein bindingDNA polymerase betaHomo sapiens (human)
microtubule bindingDNA polymerase betaHomo sapiens (human)
lyase activityDNA polymerase betaHomo sapiens (human)
enzyme bindingDNA polymerase betaHomo sapiens (human)
metal ion bindingDNA polymerase betaHomo sapiens (human)
5'-deoxyribose-5-phosphate lyase activityDNA polymerase betaHomo sapiens (human)
class I DNA-(apurinic or apyrimidinic site) endonuclease activityDNA polymerase betaHomo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
potassium channel regulator activityPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
telethonin bindingPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
protein-containing complex bindingPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
transmembrane transporter bindingPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
enzyme inhibitor activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
steroid bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
phosphatidylinositol phospholipase C activityC-C chemokine receptor type 1Homo sapiens (human)
chemokine receptor activityC-C chemokine receptor type 1Homo sapiens (human)
protein bindingC-C chemokine receptor type 1Homo sapiens (human)
C-C chemokine receptor activityC-C chemokine receptor type 1Homo sapiens (human)
C-C chemokine bindingC-C chemokine receptor type 1Homo sapiens (human)
chemokine (C-C motif) ligand 7 bindingC-C chemokine receptor type 1Homo sapiens (human)
chemokine (C-C motif) ligand 5 bindingC-C chemokine receptor type 1Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
calmodulin bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
protein phosphatase 1 bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
outward rectifier potassium channel activityPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
protein kinase A catalytic subunit bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
protein kinase A regulatory subunit bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
transmembrane transporter bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in atrial cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
ankyrin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
small molecule bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
molecular function activator activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 5 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
calmodulin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
fibroblast growth factor bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
enzyme bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein kinase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein domain specific bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ankyrin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ubiquitin protein ligase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
nitric-oxide synthase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in Purkinje myocyte action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
scaffold protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
A-type (transient outward) potassium channel activityPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
transmembrane transporter bindingPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
metal ion bindingPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (54)

Processvia Protein(s)Taxonomy
photoreceptor outer segmentVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
nucleusDNA polymerase betaHomo sapiens (human)
nucleoplasmDNA polymerase betaHomo sapiens (human)
cytoplasmDNA polymerase betaHomo sapiens (human)
microtubuleDNA polymerase betaHomo sapiens (human)
spindle microtubuleDNA polymerase betaHomo sapiens (human)
protein-containing complexDNA polymerase betaHomo sapiens (human)
nucleusDNA polymerase betaHomo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
lysosomePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
apical plasma membranePotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
Z discPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
membrane raftPotassium voltage-gated channel subfamily E member 1Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
plasma membraneUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
perinuclear region of cytoplasmUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulum chaperone complexUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cytochrome complexUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
plasma membraneC-C chemokine receptor type 1Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 1Homo sapiens (human)
external side of plasma membraneC-C chemokine receptor type 1Homo sapiens (human)
cytoplasmC-C chemokine receptor type 1Homo sapiens (human)
early endosomePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
endoplasmic reticulumPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cytoplasmPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
lysosomePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
early endosomePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
late endosomePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
endoplasmic reticulumPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
basolateral plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
apical plasma membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
transport vesiclePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
cytoplasmic vesicle membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
neuron projectionPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
neuronal cell bodyPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membrane raftPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
ciliary basePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
lumenal side of membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
basolateral part of cellPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
monoatomic ion channel complexPotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
membranePotassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
sarcoplasmic reticulumVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
T-tubuleVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
I bandVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic densityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
dendriteVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic density membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleolusSodium channel protein type 5 subunit alphaHomo sapiens (human)
endoplasmic reticulumSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
cell surfaceSodium channel protein type 5 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 5 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
lateral plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 5 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 5 subunit alphaHomo sapiens (human)
sarcolemmaSodium channel protein type 5 subunit alphaHomo sapiens (human)
perinuclear region of cytoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
sarcolemmaPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
GABA-ergic synapsePotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
postsynaptic specialization membranePotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
dendritic spinePotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
neuronal cell bodyPotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
postsynaptic membranePotassium voltage-gated channel subfamily D member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (725)

Assay IDTitleYearJournalArticle
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID556556Toxicity in patient with severe renal insufficiency at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID1736703Antiviral activity against HIV1 infected in PBMC assessed as reduction in viral replication by measuring reduction in p24 production by ELISA2020European journal of medicinal chemistry, Mar-15, Volume: 190Design, synthesis and biological evaluation of novel 2-(5-aryl-1H-imidazol-1-yl) derivatives as potential inhibitors of the HIV-1 Vpu and host BST-2 protein interaction.
AID1633400Antiviral activity against wild-type HIV1 NL4-3 infected infected in human MT2 cells assessed as reduction in HIV1 integrated DNA at 1 uM and measured after 30 hrs post infection by Alu-LTR PCR protocol based method2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Synthesis and Evaluation of Bifunctional Aminothiazoles as Antiretrovirals Targeting the HIV-1 Nucleocapsid Protein.
AID556549Renal clearance in healthy human at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID586148Antiviral activity against Human immunodeficiency virus 1 clone 50_2 harboring integrase R20K, A23V, E92G, T124N, I141V, G193E, V201I, T206S, I220V, D279G infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect relative to wi2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID364188Inhibition of CYP3A42008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID1060851Inhibition of HIV1 integrase2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis, anti-HIV activity, integrase enzyme inhibition and molecular modeling of catechol, hydroquinone and quinol labdane analogs.
AID375392Inhibition of HIV1 integrase using labelled oligonucleotide substrate by ELISA2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration of novel thiobarbituric acid-, rhodanine- and thiohydantoin-based HIV-1 integrase inhibitors.
AID759999Therapeutic index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B2013ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7
4-Substituted 2-Hydroxyisoquinoline-1,3(2H,4H)-diones as a Novel Class of HIV-1 Integrase Inhibitors.
AID541171Selectivity ratio of EC50 for antiviral activity against HIV1 harboring L74M and E92V mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID375396Cytotoxicity against human MT4 cells by MTT method2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration of novel thiobarbituric acid-, rhodanine- and thiohydantoin-based HIV-1 integrase inhibitors.
AID582864Antiviral activity against Human immunodeficiency virus 1 clone 4 harboring integrase R20K, A23V, T124N, I141V, G193E, V201I, T206S, I220V, D279G mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID1264514Antiviral activity against HIV-1 infected in human TZM-bl cells assessed as inhibition of viral replication for 48 hrs by bright-Glo luciferase assay2015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Design, Synthesis, and Biological Evaluation of 1,2-Dihydroisoquinolines as HIV-1 Integrase Inhibitors.
AID562132Terminal half life in healthy human at 400 mg/kg, po administered as single dose2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
AID586144Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase T206S mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID573997Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for MK-0518-resistant Human immunodeficiency virus harboring G140S and Q148H mutations in integrase2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID1073330Antiviral activity against HIV-1 harboring integrase Y143R mutant relative to wild type HIV12014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID1655467Inhibition of wild type recombinant HIV1 His6-tagged integrase expressed in Escherichia coli BL21 using 18 nucleotide 3'-biotin labeled DNA acceptor as substrate preincubated for 1 hr followed by substrate addition and further incubated for 90 mins in pre2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
5,6-Dihydroxypyrimidine Scaffold to Target HIV-1 Nucleocapsid Protein.
AID375395Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathogenicity by MTT assay2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration of novel thiobarbituric acid-, rhodanine- and thiohydantoin-based HIV-1 integrase inhibitors.
AID1517754Inhibition of recombinant full length HIV-1 integrase at 1 uM using biotin-labelled ds HIV-1 LTR U5 DNA as substrate preincubated for 5 mins followed by TS DNA addition and measured after 30 mins2019European journal of medicinal chemistry, Dec-01, Volume: 183Discovery of 2-isoxazol-3-yl-acetamide analogues as heat shock protein 90 (HSP90) inhibitors with significant anti-HIV activity.
AID1228821Inhibition of HIV-1 integrase assessed as inhibition of 3'-processing activity using 32P-labeled DNA as substrate after 1 hr by gel-based assay in presence of Mg2+2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
N-Substituted Quinolinonyl Diketo Acid Derivatives as HIV Integrase Strand Transfer Inhibitors and Their Activity against RNase H Function of Reverse Transcriptase.
AID1075428Antiviral activity against wild-type Human immunodeficiency virus 1 infected in HOS cells preincubated for 3 hrs followed by viral infection measured after 48 hrs by luciferase reporter gene assay2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.
AID586156Antiviral activity against Human immunodeficiency virus 1 clone 16 harboring integrase E11D, S17T, L45V, M50T, I72V, L74I, K111T, T125A relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID541174Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E92V, G140S and V151A mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1406291Inhibition of HIV1 reverse transcriptase polymerase activity using 18 nucleotide DNA primer and 100 nucleotide DNA template after 30 mins2018European journal of medicinal chemistry, Aug-05, Volume: 1566-Arylthio-3-hydroxypyrimidine-2,4-diones potently inhibited HIV reverse transcriptase-associated RNase H with antiviral activity.
AID582824AUCt in HIV-infected human plasma at 800 mg qd for 10 days administered in fasted condition on day 10 by HPLC with fluorescence detector2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.
AID584782AUC (0 to infinity) in HIV-seronegative healthy volunteers at 400 mg, po administered as single dose by LC-MS/MS2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
AID364247Antiviral activity against HIV1 with integrase T66I/S153Y mutation by single cycle infectivity assay in presence of 10%FBS2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID760004Ratio of IC50 for 3'-processing activity of HIV1 integrase to IC50 for strand transfer activity of HIV1 integrase2013ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7
4-Substituted 2-Hydroxyisoquinoline-1,3(2H,4H)-diones as a Novel Class of HIV-1 Integrase Inhibitors.
AID1191895Drug metabolism assessed as UGT1A4-mediated compound glucuronidation in pooled mixed-gender human liver microsomes at 50 uM preincubated at 37 degC for 3 mins before UDPGA addition by HPLC method2015Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6
A novel molecule with notable activity against multi-drug resistant tuberculosis.
AID1635801Inhibition of HIV1 recombinant integrase expressed in Escherichia coli using [32P]-labeled oligonucleotide as substrate after 60 mins by strand transfer activity assay2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H.
AID1053409Antiviral activity against HIV1 3B infected in human HeLa cells expressing CD4 assessed as inhibition of viral replication after 2 days by beta-galactosidase reporter gene assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
6-(1-Benzyl-1H-pyrrol-2-yl)-2,4-dioxo-5-hexenoic acids as dual inhibitors of recombinant HIV-1 integrase and ribonuclease H, synthesized by a parallel synthesis approach.
AID533666Trough drug concentration at 12 hrs in healthy human plasma at 400 mg, po twice a day for 4 days by reverse-phase HPLC-MS method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
AID721992Selectivity ratio of IC50 for RAL-resistant HIV1 harboring integrase Y143R mutant to IC50 for wild type HIV1 3B2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles.
AID1901046Inhibition of full-length recombinant HIV1 integrase at 1 uM using target substrate DNA preincubated for 5 mins followed by substrate addition and measured after 30 mins by colorimetry relative to control2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Synthesis and anti-HIV activity of a new isoxazole containing disubstituted 1,2,4-oxadiazoles analogs.
AID497131Inhibition of HIV1 integrase2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
New chloro,fluorobenzylindole derivatives as integrase strand-transfer inhibitors (INSTIs) and their mode of action.
AID1152134Resistance ratio of EC50 for raltegravir-resistant HIV1 harboring integrase G140S/Q148H double mutant to EC50 for wild type HIV12014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.
AID574945Drug level in semen of healthy human at 400 mg/kg administered twice daily measured 5 hrs post dosing by HPLC2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Raltegravir penetration in seminal plasma of healthy volunteers.
AID1635806Fold resistance, ratio of EC50 for raltegravir-resistant HIV1 1556-1 expressing integrase Y143C mutant to EC50 for HIV1 expressing wild-type integrase2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H.
AID541169Selectivity ratio of EC50 for antiviral activity against HIV1 harboring N155H mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID562138AUC(0 to 12 hrs) in healthy human at 400 mg/kg, po BID for 4 days2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
AID1264517Antiviral activity against HIV-1 NL4-3 infected in human jurkat cells assessed as decrease in p24 level at 10 uM after 48 hrs by western blot analysis2015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Design, Synthesis, and Biological Evaluation of 1,2-Dihydroisoquinolines as HIV-1 Integrase Inhibitors.
AID586131Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase L74I mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID364185Inhibition of CYP1A22008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID562353Antiviral activity against HIV1 harboring integrase N155H mutant infected in human TZM-bl cells assessed as beta-galactosidase expression after 48 hrs by microplate luminometry relative to HIV1 R7/3 expressing wild type integrase enzyme relative to HIV1 R2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors.
AID562130Tmax in healthy human at 400 mg/kg, po administered as single dose2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
AID1907129Inhibition of recombinant HIV-1 integrase strand transfer activity by enzymatic assay2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
4,5-Dihydroxypyrimidine Methyl Carboxylates, Carboxylic Acids, and Carboxamides as Inhibitors of Human Cytomegalovirus pUL89 Endonuclease.
AID541167Selectivity ratio of EC50 for antiviral activity against HIV1 harboring Q148K mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID556557Toxicity in patient with hepatic insufficiency at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID364190Plasma clearance in Sprague-Dawley rat at 3 mg/kg, iv2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID586167Antiviral activity against Human immunodeficiency virus 1 clone 13 harboring integrase S17N, T124N, T125A, G140S, M154I, S195C mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID501888Antiviral activity against HIV1 harboring integrase T66/L74M and V151L double mutant relative to wild type2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Development of 2-pyrrolidinyl-N-methyl pyrimidones as potent and orally bioavailable HIV integrase inhibitors.
AID584785Ratio of AUC (0 to 12 hrs) in HIV-seronegative healthy volunteers at 400 mg, po administered as single dose in presence of albuminium, magnesium and simethicone-containg antacid to AUC (0 to 12 hrs) in HIV-seronegative healthy volunteers at 400 mg, po adm2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
AID364250Antiviral activity against HIV1 with integrase T66I/L74M/V151I mutation by single cycle infectivity assay in presence of 10%FBS2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID553259Inhibition of strand transfer activity of HIV integrase G140S and Q148H mutant2011ACS medicinal chemistry letters, Jan, Volume: 2, Issue:1
N-3 Hydroxylation of Pyrimidine-2,4-diones Yields Dual Inhibitors of HIV Reverse Transcriptase and Integrase.
AID575616Renal clearance in healthy human at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID1075420Selectivity index, ratio of CC50 for HOS cells to EC50 for wild-type Human immunodeficiency virus 12014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.
AID562133Cmin in healthy human at 800 mg/kg, po BID for 14 days after 12 hrs in presence of 600 mg/kg, po rifampin2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
AID760001Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay2013ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7
4-Substituted 2-Hydroxyisoquinoline-1,3(2H,4H)-diones as a Novel Class of HIV-1 Integrase Inhibitors.
AID586166Antiviral activity against Human immunodeficiency virus 1 clone 11 harboring integrase S17N, I84I, T124N, T125A, M154I, S195C mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID1660998Toxicity in human THP1 cells assessed as reduction in cell viability2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent
AID586168Antiviral activity against Human immunodeficiency virus 1 clone 14 harboring integrase S17N, T124N, T125A, M154I, S195C, V201I mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID585980Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase T66I mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID587737Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef infected in human HeLa-T4 cells assessed as time required to cause 50% loss in compound potency at 10 t2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID562129Cmax in healthy human at 400 mg/kg, po administered as single dose2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
AID1365352Antiviral activity against HIV2 ROD 3B infected in human MT4 cells assessed as inhibition of viral-induced cytopathic effect by MTT assay2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
1-Hydroxypyrido[2,3-d]pyrimidin-2(1H)-ones as novel selective HIV integrase inhibitors obtained via privileged substructure-based compound libraries.
AID556544Primary phase half life in patient with severe renal insufficiency at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID586171Antiviral activity against Human immunodeficiency virus 1 clone 17 harboring integrase S17N, T124N, T125A, M154I, S195C mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID364218AUC in dog at 10 mg/kg, po2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID676992Antiplasmodial activity against Plasmodium falciparum 3D7 ring stage cells assessed as reduction parasitemia by Malstat assay2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy.
AID501889Antiviral activity against HIV1 harboring integrase T66I and S153Y double mutant relative to wild type2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Development of 2-pyrrolidinyl-N-methyl pyrimidones as potent and orally bioavailable HIV integrase inhibitors.
AID1152847Antiviral activity against Feline immunodeficiency virus infected in cat FL-4 cells assessed as viral RNA production by RT-qPCR2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Evaluation of the antiviral efficacy of bis[1,2]dithiolo[1,4]thiazines and bis[1,2]dithiolopyrrole derivatives against the nucelocapsid protein of the Feline Immunodeficiency Virus (FIV) as a model for HIV infection.
AID1053406Selectivity index, ratio of CC50 for human HeLa cells expressing CD4 to EC50 for HIV1 3B2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
6-(1-Benzyl-1H-pyrrol-2-yl)-2,4-dioxo-5-hexenoic acids as dual inhibitors of recombinant HIV-1 integrase and ribonuclease H, synthesized by a parallel synthesis approach.
AID707908Lipophilicity, log P of the compound2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Chemokine receptor antagonists.
AID525108Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 20 passages selected in presence of compound2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID575625Cmin in healthy human plasma assessed as raltegravir-glucoronide at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID556543Tmax in patient with severe renal insufficiency at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID541113Selectivity index, ratio of CC50 for human MT2 cells to EC50 for HIV1 3B in presence of 10% FBS2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1222389Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in estradiol 3-glucuronidation by LC-MS/MS method2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.
AID501884Antiviral activity against HIV1 harboring integrase T125K mutant relative to wild type2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Development of 2-pyrrolidinyl-N-methyl pyrimidones as potent and orally bioavailable HIV integrase inhibitors.
AID562123Cmax in healthy human at 400 mg/kg, po administered as single dose in presence of 600 mg/kg, po rifampin2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID556535Cmax in healthy human at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID364184Inhibition of human DNA polymerase gamma2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID1365358Selectivity index, ratio of CC50 for cytotoxic activity against mock-infected human MT4 cells to EC50 for antiviral activity against HIV2 ROD 3B infected in human MT4 cells2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
1-Hydroxypyrido[2,3-d]pyrimidin-2(1H)-ones as novel selective HIV integrase inhibitors obtained via privileged substructure-based compound libraries.
AID364245Antiviral activity against HIV1 with integrase T125K mutation by single cycle infectivity assay in presence of 10%FBS2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID1237270Inhibition of His-tagged HIV-1 integrase-mediated 3' processing and strand transfer reactions using 5'-ACAGGCCTAGCACGCGTCG-Biotin-3' annealed with 5'-CGACGCGTGGTAGGCCTGT-Biotin3'/5'-Cy5-ATGTGGAAAATCTCTAGCAGT-3' annealed with 5'-Cy5-TGAGCTCGAGATTTTCCACAT-32015Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15
Investigation on the sucrose binding pocket of HIV-1 Integrase by molecular dynamics and synergy experiments.
AID1635804Therapeutic index, ratio of CC50 for human CEM-SS cells to EC50 for HIV1 3B infected in human CEM-SS cells2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H.
AID541159Selectivity ratio of EC50 for antiviral activity against GS-9160-resistant HIV1 selected after 8 passages to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID364214Terminal half life in po dosed Sprague-Dawley rat2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID525112Antiviral activity against HIV 1 NL4.3 harboring integrase L74M mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID760007Inhibition of 3'-processing activity of HIV1 integrase using 32P-5'-TGTGGAAAATCTCTAGCAGT-3' and 5'-ACTGCTAGAGATTTTCCACA-3' as substrate after 1 hr by ELISA2013ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7
4-Substituted 2-Hydroxyisoquinoline-1,3(2H,4H)-diones as a Novel Class of HIV-1 Integrase Inhibitors.
AID574946Ratio of drug level in semen to blood in healthy human at 400 mg/kg administered twice daily measured 5 hrs post dosing by HPLC2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Raltegravir penetration in seminal plasma of healthy volunteers.
AID1406290Inhibition of HIV1 reverse transcriptase RNaseH activity using 3'-fluorescein/5'-Dabcyl labeled HTS-1 substrate2018European journal of medicinal chemistry, Aug-05, Volume: 1566-Arylthio-3-hydroxypyrimidine-2,4-diones potently inhibited HIV reverse transcriptase-associated RNase H with antiviral activity.
AID1075417Ratio of EC50 for Human immunodeficiency virus 1 harboring integrase G140S/Q148H double mutant to EC50 for wild-type Human immunodeficiency virus 12014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.
AID1186008Antiviral activity against HIV1 infected in 293T cells assessed as time of 50% failure2014European journal of medicinal chemistry, Oct-06, Volume: 852,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID1264516Therapeutic index, ratio of CC50 for human TZM-bl cells to EC50 for HIV-1 infected in TZM-bl cells2015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Design, Synthesis, and Biological Evaluation of 1,2-Dihydroisoquinolines as HIV-1 Integrase Inhibitors.
AID562122AUC (0 to infinity) in healthy human at 400 mg/kg, po administered as single dose in presence of 600 mg/kg, po rifampin2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
AID364176Inhibition of HIV1 recombinant integrase strand transfer activity2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID1075415Ratio of EC50 for Human immunodeficiency virus 1 harboring integrase E138K/Q148K double mutant to EC50 for wild-type Human immunodeficiency virus 12014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.
AID1635810Inhibition of RNase H activity of full length HIV1 reverse transcriptase using RNA-DNA duplex HTS-1 substrate2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H.
AID1442775Antiviral activity against HIV1 HXB2 pseudovirus infected in human TZM-bl cells assessed as inhibition of viral entry treated 8 hrs post infection measured after 48 hrs by luciferase reporter gene assay2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
AID496468Antiviral activity against HIV12010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.
AID582829Drug concentration at the end of dosing interval in HIV-infected human PBMC at 800 mg qd for 10 days administered in fasted condition on day 10 by LC-MS/MS analysis2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.
AID364215Terminal half life in dog at 10 mg/kg, po2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID582832Intracellular compound distribution in ratio in HIV-infected human PBMC at AUCt by LC-MS/MS analysis2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.
AID1588925Antiviral activity against HIV2 ROD infected in human MT4 cells incubated for 5 days by MTT assay2019Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17
Design, synthesis and biological evaluation of 3-hydroxyquinazoline-2,4(1H,3H)-diones as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and integrase.
AID525109Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 40 passages selected in presence of compound2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID525110Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 60 passages selected in presence of compound2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID541164Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E92V mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1635803Cytotoxicity against human CEM-SS cells assessed as cell death after 6 days by MTS assay2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H.
AID586141Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase V165I mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID497132Inhibition of HIV1 integrase strand transfer2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
New chloro,fluorobenzylindole derivatives as integrase strand-transfer inhibitors (INSTIs) and their mode of action.
AID586153Antiviral activity against Human immunodeficiency virus 1 clone 9 harboring integrase E11D, S17T, L45V, M50T, I72V, L74I, K111T, S119G, relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID364209Cmax in dog at 10 mg/kg, po2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID584790Toxicity in HIV-seronegative healthy volunteers assessed as occurrence of mild headache at 400 mg, po administered as single dose2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
AID364203Terminal half life in dog at 1 mg/kg, iv2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID541110Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS, HSA and alpha1-AGP2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1736693Antiviral activity against HIV1 LAV infected in human MT4 cells assessed as reduction in viral replication by measuring reduction in p24 expression incubated for 72 hrs by ELISA2020European journal of medicinal chemistry, Mar-15, Volume: 190Design, synthesis and biological evaluation of novel 2-(5-aryl-1H-imidazol-1-yl) derivatives as potential inhibitors of the HIV-1 Vpu and host BST-2 protein interaction.
AID569004Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV13B2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
HIV-1 integrase strand-transfer inhibitors: design, synthesis and molecular modeling investigation.
AID586164Antiviral activity against Human immunodeficiency virus 1 clone 9 harboring integrase S17N, I84I, T124N, T125A, M154I, A175T, S195C mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID1251690Resistance index, ratio of IC50 for antiviral activity against HIV1 expressing integrase N155H mutant to IC50 for antiviral activity against HIV1 expressing wild type integrase2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors.
AID331697Inhibition of HIV1 integrase2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series.
AID556533Terminal half life in patient with hepatic insufficiency at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID1483417Antiviral activity against HIV1 infected in CD4/CXCR4/CCR5 expressing human P4R5 cells assessed as inhibition of viral replication preincubated with cells for 24 hrs followed by viral infection measured after 48 hrs by beta-galactosidase reporter gene ass2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Double-Winged 3-Hydroxypyrimidine-2,4-diones: Potent and Selective Inhibition against HIV-1 RNase H with Significant Antiviral Activity.
AID575597AUC (12 to 24 hrs) in healthy human at 400 mg, po Bid for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID519017Antiviral activity against Human immunodeficiency virus 1 Ba-L infected in human PBMCs assessed as inhibition of viral replication2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
AID587736Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef infected in human HeLa-T4 cells assessed as time required to 50% inhibition of infection at 10 times EC2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID573996Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for L-870,810-resistant Human immunodeficiency virus harboring L74M, E92Q and S230N mutations in integrase2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID541154Selectivity ratio of EC50 for antiviral activity against APV-resistant HIV1 selected after 2 passages to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID413246Inhibition of HIV1 integrase2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.
AID587757Ratio of EC50 for HIV1 NL4-3.Luc assessed as infectivity using human MDM pretreated for 24 hrs followed by exposed to virus after compound washout to standard EC50 for HIV1 NL4-3.Luc2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID1152848Therapeutic index, ratio of CC50 for cat CRFK cells to EC50 for Feline immunodeficiency virus infected in cat FL-4 cells2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Evaluation of the antiviral efficacy of bis[1,2]dithiolo[1,4]thiazines and bis[1,2]dithiolopyrrole derivatives against the nucelocapsid protein of the Feline Immunodeficiency Virus (FIV) as a model for HIV infection.
AID533671Cmax in healthy human plasma at 400 mg, po twice a day for 4 days coadministered with 200mg of etravirine twice a day for 4 days by reverse-phase HPLC-MS method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
AID575612Apparent total plasma clearance in healthy human at 400 mg, po Bid for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID1261364Inhibition of recombinant HIV-1 integrase stand transfer activity expressed in Escherichia coli BL21(DE3) cells using 32P-labeled DNA substrate after 1 hr by densitometric analysis2015European journal of medicinal chemistry, Nov-02, Volume: 104Synthesis of dihydropyrimidine α,γ-diketobutanoic acid derivatives targeting HIV integrase.
AID586138Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase M154I mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID1073327Antiviral activity against HIV-1 harboring integrase Q148R mutant relative to wild type HIV12014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID364193Volume of distribution in Sprague-Dawley rat at 3 mg/kg, iv2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID1661001Distribution coefficient, logD of the compound at pH 7.4 by chromatography2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent
AID1264515Cytotoxicity against human TZM-bl cells after 48 hrs by Cell-titerGlo assay2015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Design, Synthesis, and Biological Evaluation of 1,2-Dihydroisoquinolines as HIV-1 Integrase Inhibitors.
AID585982Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase L68V mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID596555Resistant fold, ratio of IC50 for HIV1 integrase Y143R mutant strand transfer activity to IC50 for wild type HIV1 integrase strand transfer activity in presence of magnesium2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.
AID1073317Antiviral activity against HIV-1 harboring integrase T97A/Y143R double mutant relative to wild type HIV12014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID556550Ratio of AUC (0 to infinity) in patient with hepatic insufficiency to AUC (0 to infinity) in healthy human at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID1073329Antiviral activity against HIV-1 harboring integrase Q148H mutant relative to wild type HIV12014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID575611Drug level in healthy human urine at 400 mg, po Bid for 1 week measured at 12 to 24 hrs post dose by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID717577Ratio of EC50 for HIV1 expressing integrase G140S/Q148H mutant to EC50 for HIV1 expressing wild type integrase2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
6,7-Dihydroxy-1-oxoisoindoline-4-sulfonamide-containing HIV-1 integrase inhibitors.
AID562345Antiviral activity against HIV1 R-31 harboring integrase D10E, E11D, V32I, V37I, V72I, L101I, T112I, A124N, T125A, K173R, A205S, Q216H, N222K, S230N, N232D mutant gene infected in human TZM-bl cells assessed as beta-galactosidase expression after 48 hrs b2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors.
AID584788Ratio of Tmax in HIV-seronegative healthy volunteers at 400 mg, po administered as single dose in presence of albuminium, magnesium and simethicone-containg antacid to Tmax in HIV-seronegative healthy volunteers at 400 mg, po administered as single dose2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
AID591589Ratio of IC50 for Human immunodeficiency virus 1 NL4-3 integrase N155H mutant to IC50 for wild-type Human immunodeficiency virus 1 NL4-3 integrase2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integrase.
AID364204Volume of distribution in dog at 1 mg/kg, iv2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID584794Ratio of drug level in HIV-infected patients at 400 mg, po treated after 2 hrs administration of 20 mg proton pump inhibitor omeprazole after 12 hrs to drug level in HIV-infected patients at 400 mg, po after 12 hrs2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
AID364216Terminal half life in po dosed rhesus monkey2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID541157Selectivity ratio of EC50 for antiviral activity against GS-9160-resistant HIV1 selected after 6 low passages to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID587752Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef assessed as suppression of 2 mins magnetic nanopartials-medated residual infection in human HeLaT4 cell2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID1635808Fold resistance, ratio of EC50 for raltegravir-resistant HIV1 8070-1 expressing integrase G140S/Y143H/Q148H mutant to EC50 for HIV1 expressing wild-type integrase2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H.
AID1610045Antiviral activity against HIV1 NL4.3 infected in human TZM-bl cells measured upto 24 hrs by bright Glo-luciferase reporter gene assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.
AID519038Inhibition of Human immunodeficiency virus 1 integrase by strand transfer scintillation proximity assay2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
AID417575Antiviral activity against HIV1 3B infected in human MT2 cells after 5 days by chemiluminescence in presence of human serum albumin2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Tricyclic HIV integrase inhibitors V. SAR studies on the benzyl moiety.
AID1483418Cytotoxicity against human P4R5 cells by MTS assay2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Double-Winged 3-Hydroxypyrimidine-2,4-diones: Potent and Selective Inhibition against HIV-1 RNase H with Significant Antiviral Activity.
AID1237269Inhibition of His-tagged HIV-1 integrase-mediated 3' processing and strand transfer reactions using 5'-ACAGGCCTAGCACGCGTCG-Biotin-3' annealed with 5'-CGACGCGTGGTAGGCCTGT-Biotin3'/5'-Cy5-ATGTGGAAAATCTCTAGCAGT-3' annealed with 5'-Cy5-TGAGCTCGAGATTTTCCACAT-32015Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15
Investigation on the sucrose binding pocket of HIV-1 Integrase by molecular dynamics and synergy experiments.
AID584779Cmax in HIV-seronegative healthy volunteers at 400 mg, po administered as single dose by LC-MS/MS in presence of albuminium, magnesium and simethicone-containg antacid2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
AID1605432Antiviral activity against HIV1 NL4-3 harboring G140S/Q148H mutant infected in human MT2 cells measured after 3 to 4 days by luciferase reporter gene assay2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
Discovery and Optimization of Novel Pyrazolopyrimidines as Potent and Orally Bioavailable Allosteric HIV-1 Integrase Inhibitors.
AID556537Tmax in healthy human at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID508283Antiviral activity against Human immunodeficiency virus 1 clone 4736_2 harboring integrase N155H,T97A and D6E, S17N, R20K, D25E, S39C, L45V,L101I, V201I, S119R, T124A, K160T, K211R, D288N mutation transfected into human C8166 cells assessed as decrease in2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector.
AID1207765Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits2013Scientific reports, , Volume: 3MICE models: superior to the HERG model in predicting Torsade de Pointes.
AID575619Cmin in healthy human plasma assessed as raltegravir-glucoronide at 400 mg, po Bid for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID1193106Cytotoxicity against cat CRFK cells assessed as cell viability at 10 uM after 24 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6
Novel fused tetrathiocines as antivirals that target the nucleocapsid zinc finger containing protein of the feline immunodeficiency virus (FIV) as a model of HIV infection.
AID1228826Cytotoxicity against human HeLa-CD4-LTR-beta-gal cells after 24 hrs by ATPlite reagent based luminescence analysis2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
N-Substituted Quinolinonyl Diketo Acid Derivatives as HIV Integrase Strand Transfer Inhibitors and Their Activity against RNase H Function of Reverse Transcriptase.
AID575599Trough plasma concentration in healthy human at 400 mg, po Bid for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID574942Drug level in semen of healthy human at 400 mg/kg administered twice daily measured after 2 to 4 hrs by HPLC2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Raltegravir penetration in seminal plasma of healthy volunteers.
AID1251685Antiviral activity against HIV1 infected in human MT4 cells expressing GFP incubated for 48 to 72 hrs in presence of 50% normal human serum by multiple round viral replication kinetics assay2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors.
AID541170Selectivity ratio of EC50 for antiviral activity against HIV1 harboring N155S mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID587739Cytotoxicity against human HeLaT4 cells by WST-1 assay2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID562131Primary phase half life in healthy human at 400 mg/kg, po administered as single dose2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
AID1300999Selectivity ratio of EC50 for raltegravir resistant HIV1 harboring integrase Q148H mutant infected in human MT4 cells to EC50 for wild type HIV1 infected in human MT4 cells2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID1075418Ratio of EC50 for Human immunodeficiency virus 1 harboring integrase N155H mutant to EC50 for wild-type Human immunodeficiency virus 12014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.
AID1298357Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in U5-gag level at 50 or 100 nM measured at 72 hrs post infection by qPCR method2016Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11
Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID331700Cytotoxicity against human MT4 cells2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series.
AID541153Selectivity ratio of EC50 for antiviral activity against EFV-resistant HIV1 selected after 7 passages to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1073337Antiviral activity against HIV-1 harboring integrase T66R mutant relative to wild type HIV12014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID1635809Fold resistance, ratio of EC50 for raltegravir-resistant HIV1 8070-2 expressing integrase G140S/Q148H mutant to EC50 for HIV1 expressing wild-type integrase2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H.
AID533884Trough plasma concentration at 12 hrs in HIV-negative human at 400 mg, po administered as single dose2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
AID587756Ratio of EC50 for HIV1 NL4-3.Luc assessed as infectivity using human PBMC pretreated for 24 hrs followed by exposed to virus after compound washout to standard EC50 for HIV1 NL4-3.Luc2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID556558Toxicity in human assessed as headache at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID1450147Cytotoxicity against human TZM-b1 cells by XTT assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
One drug for two targets: Biological evaluation of antiretroviral agents endowed with antiproliferative activity.
AID1565228Inhibition of His-tagged HIV-1 integrase interaction with HIV-1 FLAG-tagged LEDGF/p75 expressed in Escherichia coli BL21(DE3) cells incubated for 30 mins followed by LEDGF addition measured after 4 hrs by HTRF assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Chromenone derivatives as a versatile scaffold with dual mode of inhibition of HIV-1 reverse transcriptase-associated Ribonuclease H function and integrase activity.
AID556541Cmax in patient with severe renal insufficiency at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID434440Inhibition of recombinant HIV-1 integrase strand transfer activity2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center.
AID586174Antiviral activity against Human immunodeficiency virus 1 clone 2 harboring integrase R20K, A23V, E92G, T124N, I141V, G193E, V201I, T206S, I220V, D279G mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID364181Inhibition of HIV ribonuclease H2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID575602Ctau in healthy human plasma at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID582872Antiviral activity against Human immunodeficiency virus 1 clone 15_7 harboring integrase T97A mutant and T97A, Y143R site-directed mutation relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID1053407Cytotoxicity against human HeLa cells expressing CD4 after 24 hrs by beta-galactosidase reporter gene assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
6-(1-Benzyl-1H-pyrrol-2-yl)-2,4-dioxo-5-hexenoic acids as dual inhibitors of recombinant HIV-1 integrase and ribonuclease H, synthesized by a parallel synthesis approach.
AID586150Antiviral activity against Human immunodeficiency virus 1 clone 5 harboring integrase E11D, S17T, S39G, L45V, M50I, I72V, L74I, K111T, S119G, T125A relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID1660999Intrinsic clearance in mouse liver microsomes2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent
AID612820Inhibition of HIV1 recombinant integrase 3'-processing and strand transfer activity using 21-mer U5B/U5A duplex oligonucleotides after 1 hr2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Ethyl malonate amides: a diketo acid offspring fragment for HIV integrase inhibition.
AID501886Antiviral activity against HIV1 harboring integrase N155S mutant relative to wild type2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Development of 2-pyrrolidinyl-N-methyl pyrimidones as potent and orally bioavailable HIV integrase inhibitors.
AID1565227Inhibition of multimerization of of His and Flag-tagged HIV-1 integrase expressed in Escherichia coli BL21(DE3) cells at 100 uM after 2.5 hrs by HTRF assay relative to control2019European journal of medicinal chemistry, Nov-15, Volume: 182Chromenone derivatives as a versatile scaffold with dual mode of inhibition of HIV-1 reverse transcriptase-associated Ribonuclease H function and integrase activity.
AID587754Antiviral activity against HIV1 NL4-3.Luc in human PBMC assessed as infectivity treated for 24 hrs by luciferase assay2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID676996Cytotoxicity against human HeLa cells by MTT assay2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy.
AID1207382Inhibition of slow delayed inward rectifying potassium current (Iks) in Chinese Hamster Ovary (CHO) cells expressing hKvLQT1/hminK measured using IonWorks Quattro automated patch clamp platform
AID508288Antiviral activity against Human immunodeficiency virus 1 clone 8070_1 harboring integrase G140S, Y143H,Q148H and K14R, L101I, T112A, G193E, D229E, D279G mutation in transfected in human C8166 cells assessed as decrease in compound susceptibility relative2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector.
AID575605AUC (12 to24 hrs) in healthy human at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID575598AUC (0 to tau) in healthy human at 400 mg, po Bid for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID586154Antiviral activity against Human immunodeficiency virus 1 clone 12 harboring integrase E11D, S17T, L45V, M50T, I72V, L74I, K111T, S119G, T125A relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID556555Ratio of plasma concentration in patient with hepatic insufficiency to plasma concentration in healthy human at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID533686Trough plasma concentration at 12 hrs in HIV-negative human at 400 mg, po administered as single dose followed by 4 days wash out period followed by efavirenz dosing at 600 mg, po bid for 14 days coadministered with compound at 400 mg, po on day 122008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
AID508286Antiviral activity against Human immunodeficiency virus 1 clone 4736_10 harboring integrase N155H, V151I, G163R and D6E, S17N, R20K, D25E, S39C, L45V, L101I, T124A, K160T, V201I, K211R, D288N mutation transfected in human C8166 cells assessed as decrease 2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector.
AID364199Primary phase half life in rhesus monkey at 1 mg/kg, iv2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID1152845Cytotoxicity against cat CRFK cells assessed as cell viability at 10 uM after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Evaluation of the antiviral efficacy of bis[1,2]dithiolo[1,4]thiazines and bis[1,2]dithiolopyrrole derivatives against the nucelocapsid protein of the Feline Immunodeficiency Virus (FIV) as a model for HIV infection.
AID497133Antiviral activity against HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
New chloro,fluorobenzylindole derivatives as integrase strand-transfer inhibitors (INSTIs) and their mode of action.
AID533688Primary phase half life in HIV-negative human at 400 mg, po administered as single dose followed by 4 days wash out period followed by ritonavir dosing at 100 mg, po bid for 16 days coadministered with compound at 400 mg, po on day 142008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
AID1207476Inhibition of rapid delayed inward rectifying potassium current (IKr) in Chinese hamster ovary (CHO) K1 cells stably expressing hERG measured using IonWorks Quattro automated patch clamp platform
AID1207536Inhibition of rapid delayed inward rectifying potassium current (IKr) measured using manual patch clamp assay
AID575626Ctau in healthy human plasma assessed as raltegravir-glucoronide at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID595929Inhibition of HIV1 recombinant integrase 3'-processing activity expressed in Escherichia coli after 60 mins using [32P]-labeled oligonucleotide as a substrate by densitometric analysis in presence of cofactor magnesium2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.
AID1207411Inhibition of slow delayed inward rectifying potassium current (Iks) in Chinese Hamster Ovary (CHO) cells transfected with KCNQ1 / Kv1.7 / KvLQT1 and KCNE1/minK measured using IonWorks automated patch clamp platform
AID1152124Cytotoxicity against human MT4 cells infected with HIV-1 3B assessed as reduction in cell viability by MTT assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.
AID1406292Inhibition of HIV integrase strand transfer activity using 5'-biotin/3'-Cy5-labeled DNA substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by HTS assay2018European journal of medicinal chemistry, Aug-05, Volume: 1566-Arylthio-3-hydroxypyrimidine-2,4-diones potently inhibited HIV reverse transcriptase-associated RNase H with antiviral activity.
AID1073328Antiviral activity against HIV-1 harboring integrase Q148K mutant relative to wild type HIV12014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID586135Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase S119G mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID1602242Inhibition of HIV1 reverse transcriptase polymerase using deoxynucleotide triphosphates and 18 nucleotide DNA primer annealed to 100 nucleotide DNA template after 30 mins2019European journal of medicinal chemistry, Mar-15, Volume: 166Pharmacophore-based design of novel 3-hydroxypyrimidine-2,4-dione subtypes as inhibitors of HIV reverse transcriptase-associated RNase H: Tolerance of a nonflexible linker.
AID596554Resistant fold, ratio of IC50 for HIV1 integrase G140S/Q148H mutant strand transfer activity to IC50 for wild type HIV1 integrase strand transfer activity in presence of magnesium2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.
AID556528AUC (0 to infinity) in patient with hepatic insufficiency at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID582876Antiviral activity against Human immunodeficiency virus 1 HXB2 assessed as inhibition of virus induced cytopathic effect relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID582865Antiviral activity against Human immunodeficiency virus 1 clone 6 harboring integrase R20K, A23V, T124N, G193E, V201I, T206S, I220V, D279G mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID574941Ratio of drug level in semen to blood in healthy human at 400 mg/kg administered twice daily measured on day 5 by HPLC2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Raltegravir penetration in seminal plasma of healthy volunteers.
AID586163Antiviral activity against Human immunodeficiency virus 1 clone 5 harboring integrase S17N, I84I, T124N, T125A, M154I, S195C mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID584787Ratio of Cmax in HIV-seronegative healthy volunteers at 400 mg, po administered as single dose in presence of albuminium, magnesium and simethicone-containg antacid to Cmax in HIV-seronegative healthy volunteers at 400 mg, po administered as single dose2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
AID584796Primary phase half life in human at 400 mg BID2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
AID364206Oral bioavailability in po dosed dog2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID519018Displacement of 20 nM [3H]GSK304649 from Human immunodeficiency virus 1 integrase by scintillation proximity assay2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
AID1207291Inhibition of long-lasting type calcium current (ICaL) in HEK293 cells (alpha1C/beta2a/alpha2delta1) cells measured using IonWorks Barracuda automated patch clamp platform
AID364207Oral bioavailability in po dosed rhesus monkey2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID676994Antiviral activity against VSV-G pseudotyped HIV1 lentiviral particles infected in human HeLa cells incubated for 48 hrs by spectrofluorometry2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy.
AID1565222Inhibition of LEDGF/p75-dependent full length HIV-1 integrase expressed in Escherichia coli BL21(DE3) cells preincubated for 1 hr further incubated for 90 mins with biotin-labeled donor DNA and target DNA by HTRF assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Chromenone derivatives as a versatile scaffold with dual mode of inhibition of HIV-1 reverse transcriptase-associated Ribonuclease H function and integrase activity.
AID575593Cmin in healthy human plasma at 400 mg, po Bid for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID1060854Therapeutic index, ratio of CC50 for human TZM-bl cells to IC50 for HIV1 NL4.3 infected in human TZM-bl cells2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis, anti-HIV activity, integrase enzyme inhibition and molecular modeling of catechol, hydroquinone and quinol labdane analogs.
AID1483416Selectivity index, ratio of IC50 for HIV integrase strand transfer activity to IC50 for recombinant full length HIV1 reverse transcriptase RNase H domain2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Double-Winged 3-Hydroxypyrimidine-2,4-diones: Potent and Selective Inhibition against HIV-1 RNase H with Significant Antiviral Activity.
AID586132Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase L74M mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID1503546Inhibition of HIV1 integrase pre-incubated for 10 mins before DNA substrate addition and measured after 30 mins2017European journal of medicinal chemistry, Dec-01, Volume: 141Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H.
AID519041Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus infected in human MT-4 cells assessed as inhibition of viral replication2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
AID587747Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef assessed as level of infection using human HeLaT4 cells pretreated for 24 hrs followed by exposed to vi2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID1073323Antiviral activity against HIV-1 harboring integrase E92Q/N155H double mutant relative to wild type HIV12014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID582828Drug concentration at the end of dosing interval in HIV-infected human plasma at 800 mg qd for 10 days administered in fasted condition on day 10 by HPLC with fluorescence detector2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.
AID541162Selectivity ratio of EC50 for antiviral activity against HIV1 harboring L74M mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID364213Cmax in po dosed rhesus monkey2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID364249Antiviral activity against HIV1 with integrase T125K/F121Y mutation by single cycle infectivity assay in presence of 10%FBS2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID497135Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 cells2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
New chloro,fluorobenzylindole derivatives as integrase strand-transfer inhibitors (INSTIs) and their mode of action.
AID364248Antiviral activity against HIV1 with integrase N155S mutation by single cycle infectivity assay in presence of 10%FBS2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID1193107Cytotoxicity against IL2-independent cat FL-4 cells assessed as reduction in cell viability after 7 days by MTT assay2015Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6
Novel fused tetrathiocines as antivirals that target the nucleocapsid zinc finger containing protein of the feline immunodeficiency virus (FIV) as a model of HIV infection.
AID1228827Selectivity index, ratio of CC50 for human HeLa-CD4-LTR-beta-gal cells to EC50 for HIV-1 3B infected in human HeLa-CD4-LTR-beta-gal cells2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
N-Substituted Quinolinonyl Diketo Acid Derivatives as HIV Integrase Strand Transfer Inhibitors and Their Activity against RNase H Function of Reverse Transcriptase.
AID1552564Inhibition of recombinant HIV1 integrase strand transfer activity using biotin-labeled double-stranded HIV1 LTR U5 donor DNA substrate pretreated for 5 mins followed by substrate addition and measured after 30 mins by ELISA2019Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16
Biological evaluation of molecules of the azaBINOL class as antiviral agents: Inhibition of HIV-1 RNase H activity by 7-isopropoxy-8-(naphth-1-yl)quinoline.
AID562347Antiviral activity against HIV1 B-27 harboring integrase D10E, R20K, S39C, V72I, A124N, T125M, V201I, N232D mutant gene infected in human TZM-bl cells assessed as beta-galactosidase expression after 48 hrs by microplate luminometry relative to HIV1 R7/3 e2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors.
AID1191896Drug metabolism assessed as UGT1A6-mediated compound glucuronidation in pooled mixed-gender human liver microsomes at 50 uM preincubated at 37 degC for 3 mins before UDPGA addition by HPLC method2015Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6
A novel molecule with notable activity against multi-drug resistant tuberculosis.
AID595930Inhibition of HIV1 recombinant integrase 3'-processing activity expressed in Escherichia coli after 60 mins using [32P]-labeled oligonucleotide as a substrate by densitometric analysis in presence of cofactor manganese2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.
AID575634Renal clearance in healthy human assessed as raltegravir-glucoronide at 400 mg, po Bid for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID587744Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef assessed as level of infection using human HeLaT4 cells pretreated at 100 time EC95 for 24 hrs followed2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID1365356Inhibition of HIV1 recombinant integrase strand transfer activity at 5 ug/ml using biotin-labeled double-stranded HIV-1 LTR U5 donor DNA substrate incubated for 5 mins after substrate addition for 30 mins by ELISA2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
1-Hydroxypyrido[2,3-d]pyrimidin-2(1H)-ones as novel selective HIV integrase inhibitors obtained via privileged substructure-based compound libraries.
AID541168Selectivity ratio of EC50 for antiviral activity against HIV1 harboring V151A mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1588923Inhibition of HIV1 reverse transcriptase RNase H activity expressed in Escherichia coli using 32P-labeled template 31Trna RNA and DNA oligonucleotide 21P2019Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17
Design, synthesis and biological evaluation of 3-hydroxyquinazoline-2,4(1H,3H)-diones as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and integrase.
AID314171Inhibition of HIV integrase strand transfer activity2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Tricyclic HIV integrase inhibitors: potent and orally bioavailable C5-aza analogs.
AID1191894Drug metabolism assessed as UGT1A1-mediated compound glucuronidation in pooled mixed-gender human liver microsomes at 50 uM preincubated at 37 degC for 3 mins before UDPGA addition by HPLC method2015Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6
A novel molecule with notable activity against multi-drug resistant tuberculosis.
AID575607Trough plasma concentration in healthy human at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID584784AUC (0 to 12 hrs) in HIV-seronegative healthy volunteers at 400 mg, po administered as single dose by LC-MS/MS2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
AID1152119Resistance ratio of EC50 for raltegravir-resistant HIV1 harboring integrase Q148H mutant to EC50 for wild type HIV12014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.
AID364178Antiviral activity against HIV1 3B in human MT4 cells in presence of 50% normal human serum2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID562344Antiviral activity against HIV1 R-6 harboring integrase D10E, E11D, S17N, A23V, L28I, P30A, V72I, L101I, S119T, T122I, A124T, V201I, N222D, N232D, S230G, D253E, N254G mutant gene infected in human TZM-bl cells assessed as beta-galactosidase expression aft2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors.
AID1126728Antiviral activity against HIV1 3B infected in human HeLa cells expressing CD4-LTR-beta-gal assessed as inhibition of viral replication after 3 days by reporter gene assay2014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Basic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse transcriptase.
AID1588924Antiviral activity against HIV1 3B infected in human MT4 cells incubated for 5 days by MTT assay2019Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17
Design, synthesis and biological evaluation of 3-hydroxyquinazoline-2,4(1H,3H)-diones as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and integrase.
AID1126729Cytotoxicity against human HeLa cells expressing CD4-LTR-beta-gal after 24 hrs by ATPlite assay2014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Basic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse transcriptase.
AID575510Cmax in healthy human plasma at 400 mg, po Bid for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID1251687Resistance index, ratio of IC50 for antiviral activity against HIV1 expressing integrase Y143R mutant to IC50 for antiviral activity against HIV1 expressing wild type integrase2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors.
AID1228824Inhibition of RNase H function of HIV1 reverse transcriptase using DNA/RNA hybrid as substrate by fluorescence spectrometer analysis2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
N-Substituted Quinolinonyl Diketo Acid Derivatives as HIV Integrase Strand Transfer Inhibitors and Their Activity against RNase H Function of Reverse Transcriptase.
AID364243Antiviral activity against HIV1 with integrase V151I mutation by single cycle infectivity assay in presence of 10%FBS2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID508287Antiviral activity against Human immunodeficiency virus 1 clone 1556 harboring integrase Y143C, L74M, T97A, S230R, K7R, S17N, R20K, L101I, K111Q, T112K, S119R, T206S, D256E, V259I mutation transfected in human C8166 cells assessed as decrease in compound 2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector.
AID569000Inhibition of HIV-1 integrase after 1 hr by ELISA2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
HIV-1 integrase strand-transfer inhibitors: design, synthesis and molecular modeling investigation.
AID1191898Drug metabolism assessed as UGT2B7-mediated compound glucuronidation in pooled mixed-gender human liver microsomes at 50 uM preincubated at 37 degC for 3 mins before UDPGA addition by HPLC method2015Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6
A novel molecule with notable activity against multi-drug resistant tuberculosis.
AID556547Drug level in healthy human urine assessed as recovery of unchanged drug at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID584792Ratio of AUC (0 to infinity) in HIV-infected patients at 400 mg, po treated after 2 hrs administration of 20 mg proton pump inhibitor omeprazole to AUC (0 to infinity) in HIV-infected patients at 400 mg, po2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
AID533682Primary phase half life in HIV-negative human at 400 mg, po administered as single dose followed by 4 days wash out period followed by efavirenz dosing at 600 mg, po bid for 14 days coadministered with compound at 400 mg, po on day 122008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
AID717579Ratio of EC50 for HIV1 expressing integrase Y143R mutant to EC50 for HIV1 expressing wild type integrase2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
6,7-Dihydroxy-1-oxoisoindoline-4-sulfonamide-containing HIV-1 integrase inhibitors.
AID1298363Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in gag level at 50 or 100 nM measured at 72 hrs post infection by qPCR method2016Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11
Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID582834Intracellular compound distribution in ratio in HIV-infected human PBMC at Ctau by LC-MS/MS analysis2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.
AID717578Ratio of EC50 for HIV1 expressing integrase N155H mutant to EC50 for HIV1 expressing wild type integrase2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
6,7-Dihydroxy-1-oxoisoindoline-4-sulfonamide-containing HIV-1 integrase inhibitors.
AID1361065Inhibition of recombinant HIV1 integrase strand transfer activity using biotin-labeled double-stranded HIV-1 LTR U5 donor DNA substrate pretreated for 5 mins followed by substrate addition and measured after 30 mins by ELISA2018European journal of medicinal chemistry, Jul-15, Volume: 1555-Hydroxypyrido[2,3-b]pyrazin-6(5H)-one derivatives as novel dual inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H and integrase.
AID1298356Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in U5-gag level at 5 to 200 nM measured at 6 to 12 hrs post infection by qPCR method2016Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11
Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID562137Cmin in healthy human at 400 mg/kg, po BID for 4 days after 12 hrs2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
AID1075419Ratio of EC50 for Human immunodeficiency virus 1 harboring integrase Y143R mutant to EC50 for wild-type Human immunodeficiency virus 12014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.
AID1075421Antiviral activity against Human immunodeficiency virus 1 harboring integrase G140S/Q148H double mutant infected in HOS cells preincubated for 3 hrs followed by viral infection measured after 48 hrs by luciferase reporter gene assay2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.
AID508282Antiviral activity against Human immunodeficiency virus 1 clone 1288 harboring integrase M154L and E11D, V31I, L101I, K160R, F181L,V201I, T206S, D256E mutation transfected into human C8166 cells assessed as decrease in compound susceptibility relative to 2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector.
AID591591Fold resistance, ratio of EC50 for raltegravir-resistant Human immunodeficiency virus 1 1556-1 expressing integrase Y143C mutant to EC50 for raltegravir-resistant Human immunodeficiency virus 1 1556-1 expressing wild-type integrase2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integrase.
AID533695Tmax in HIV-negative human at 400 mg, po administered as single dose2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
AID364179Inhibition of HCV polymerase2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID1635807Fold resistance, ratio of EC50 for raltegravir-resistant HIV1 4736-2 expressing integrase N155H mutant to EC50 for HIV1 expressing wild-type integrase2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H.
AID533683Tmax in HIV-negative human at 400 mg, po administered as single dose followed by 4 days wash out period followed by efavirenz dosing at 600 mg, po bid for 14 days coadministered with compound at 400 mg, po on day 122008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
AID1503545Inhibition of polymerase activity of recombinant HIV1 reverse polymerase assessed as reduction in extension of an 18 nucleotide DNA primer using template/primer and dNTPs incubated for 30 mins2017European journal of medicinal chemistry, Dec-01, Volume: 141Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H.
AID541156Selectivity ratio of EC50 for antiviral activity against GS-9160-resistant HIV1 selected after 5 passages to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID569002Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
HIV-1 integrase strand-transfer inhibitors: design, synthesis and molecular modeling investigation.
AID1073325Antiviral activity against HIV-1 harboring integrase R263K mutant relative to wild type HIV12014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID556554Ratio of Cmax in patient with severe renal insufficiency to Cmax in healthy human at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID586130Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase I72V mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID582870Antiviral activity against Human immunodeficiency virus 1 clone 17 harboring integrase R20K, A23V, T124N,A129T, I141V, I62T, G193E, V201I, T206S, I220V, D279G mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID1264511Inhibition of HIV-1 integrase strand transfer activity at 10 uM preincubated for 30 mins followed by addition of FITC-labelled dsDNA for 1 hr by microplate reader analysis2015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Design, Synthesis, and Biological Evaluation of 1,2-Dihydroisoquinolines as HIV-1 Integrase Inhibitors.
AID1264513Inhibition of HIV-1 integrase G140S mutant strand transfer activity preincubated for 30 mins followed by addition of FITC-labelled dsDNA for 1 hr by microplate reader analysis2015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Design, Synthesis, and Biological Evaluation of 1,2-Dihydroisoquinolines as HIV-1 Integrase Inhibitors.
AID562352Antiviral activity against HIV1 harboring integrase T97A mutant infected in human TZM-bl cells assessed as beta-galactosidase expression after 48 hrs by microplate luminometry relative to HIV1 R7/3 expressing wild type integrase enzyme relative to HIV1 R72009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors.
AID533689Tmax in HIV-negative human at 400 mg, po administered as single dose followed by 4 days wash out period followed by ritonavir dosing at 100 mg, po bid for 16 days coadministered with compound at 400 mg, po on day 142008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
AID574939Drug level in semen of healthy human at 400 mg/kg administered twice daily measured on day 5 by HPLC2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Raltegravir penetration in seminal plasma of healthy volunteers.
AID508285Antiviral activity against Human immunodeficiency virus 1 clone 4736_9 harboring integrase N155H, E92Q H51Y and D6E, S17N, R20K, D25E, S39C, D41H, L45V, L101I, T124A, K160T, V201I,K211R, D288N mutation transfected in human C8166 cells assessed as decrease2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector.
AID573970Inhibition of Human immunodeficiency virus 1 integrase2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID1126724Inhibition of HIV1 RNase H function of recombinant reverse transcriptase using an 18-nt 3'-fluorescein-labeled RNA annealed to complementary 18-nt 5'-dabsyl-labeled DNA as substrate at 10 uM after 10 mins by fluorescence spectrometer analysis2014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Basic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse transcriptase.
AID574944Ratio of drug level in semen to blood in healthy human at 400 mg/kg administered twice daily measured after 2 to 4 hrs by HPLC2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Raltegravir penetration in seminal plasma of healthy volunteers.
AID562134AUC(0 to 12 hrs) in healthy human at 800 mg/kg, po BID for 14 days in presence of 600 mg/kg, po rifampin2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
AID573998Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for CHI/1043-resistant Human immunodeficiency virus harboring T66I and Q146K mutations in integrase2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID1073334Antiviral activity against HIV-1 harboring integrase G118R mutant relative to wild type HIV12014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID595931Inhibition of HIV1 recombinant integrase strand transfer activity expressed in Escherichia coli after 60 mins using [32P]-labeled oligonucleotide as a substrate by densitometric analysis in presence of cofactor magnesium2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.
AID587734Antiviral activity against HIV1 NL4-3.Luc assessed as infectivity using human MDM pretreated for 24 hrs followed by exposed to virus after compound washout measured after 2 to 3 days by luciferase assay2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID575609Drug level in healthy human urine at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week measured at 12 to 24 hrs post dose by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID596558Antiviral activity against HIV1 harboring wild-type integrase infected in human HOS cells2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.
AID1193108Antiviral activity against Feline immunodeficiency virus infected in cat FL-4 cells assessed as inhibition of viral replication after 7 days by quantitative RT-PCR analysis2015Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6
Novel fused tetrathiocines as antivirals that target the nucleocapsid zinc finger containing protein of the feline immunodeficiency virus (FIV) as a model of HIV infection.
AID596559Resistant fold, ratio of EC50 for HIV1 harboring integrase G140S/Q148H mutant to EC50 for HIV1 harboring wild-type integrase2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.
AID586172Antiviral activity against Human immunodeficiency virus 1 clone 18 harboring integrase S17N, I84I, T124N, T125A, M154I, S195C, V201I, S230G mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID1301000Selectivity ratio of EC50 for raltegravir resistant HIV1 harboring integrase N155H mutant infected in human MT4 cells to EC50 for wild type HIV1 infected in human MT4 cells2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID575613Renal clearance in healthy human at 400 mg, po Bid for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID586158Antiviral activity against Human immunodeficiency virus 1 clone 20 harboring integrase E11D, S17T, L45V, M50T, I72V, L74I, K111T, T125A, I217V relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID562350Antiviral activity against HIV1 G-4 harboring integrase K7R, D10E, S39C, L74I, K156R, K215N, T218I, N232D, L234I mutant gene infected in human TZM-bl cells assessed as beta-galactosidase expression after 48 hrs by microplate luminometry relative to HIV1 R2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors.
AID525106Antiviral activity against HIV 1 3B harboring integrase E92Q, S230N and L34M triple mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 60 passages in presence of compound2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID591592Fold resistance, ratio of EC50 for raltegravir-resistant Human immunodeficiency virus 1 4736-2 expressing integrase N155H mutant to EC50 for raltegravir-resistant Human immunodeficiency virus 1 4736-2 expressing wild-type integrase2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integrase.
AID585981Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase E92Q mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID1207442Inhibition of transient outward potassium current (Ito) current in Chinese Hamster Ovary (CHO) K1 cells expressing human Kv4.3 measured using IonWorks Quattro automated patch clamp platform
AID575594Ctau in healthy human plasma at 400 mg, po Bid for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID1073335Antiviral activity against HIV-1 harboring integrase T97A mutant relative to wild type HIV12014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID582831Terminal phase half life in HIV-infected human PBMC at 800 mg qd for 10 days administered in fasted condition on day 10 by LC-MS/MS analysis2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.
AID541172Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E92V and V151A mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID562348Antiviral activity against HIV1 B-28 harboring integrase D10E, R20K, S39C, V72I, A124N, T125V, V201I, N232D mutant gene infected in human TZM-bl cells assessed as beta-galactosidase expression after 48 hrs by microplate luminometry relative to HIV1 R7/3 e2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors.
AID533687Terminal half life in HIV-negative human at 400 mg, po administered as single dose followed by 4 days wash out period followed by ritonavir dosing at 100 mg, po bid for 16 days coadministered with compound at 400 mg, po on day 142008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
AID587748Ratio of EC50 for single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef assessed as level of infection using human HeLaT4 cells pretreated for 24 hrs followed by exposed to virus immed2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID1483414Inhibition of recombinant full length HIV1 reverse transcriptase polymerase domain assessed as decrease in extension of 18 nucleotide DNA primer annealed to 100 nucleotide DNA template after 30 mins2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Double-Winged 3-Hydroxypyrimidine-2,4-diones: Potent and Selective Inhibition against HIV-1 RNase H with Significant Antiviral Activity.
AID562342Antiviral activity against HIV1 F-15 harboring integrase D10E, K42T, A124N, T125A, V126L, M154L, V201I, T206S, N232D, V281S mutant gene infected in human TZM-bl cells assessed as beta-galactosidase expression after 48 hrs by microplate luminometry relativ2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors.
AID1503544Inhibition of RNH activity of recombinant HIV1 reverse transcriptase RNase H assessed as reduction in internal cleavage of RNA strand using RNA/DNA duplex substrate HTS-12017European journal of medicinal chemistry, Dec-01, Volume: 141Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H.
AID586133Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase E92G mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID519016Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT-4 cells assessed as inhibition of viral replication2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
AID1228825Antiviral activity against HIV-1 3B infected in human HeLa-CD4-LTR-beta-gal cells assessed as inhibition of viral replication by SpectraMax GEMINI-XS plate reader analysis2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
N-Substituted Quinolinonyl Diketo Acid Derivatives as HIV Integrase Strand Transfer Inhibitors and Their Activity against RNase H Function of Reverse Transcriptase.
AID1073324Antiviral activity against HIV-1 harboring integrase T66I/R263K double mutant relative to wild type HIV12014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID596553Inhibition of HIV1 recombinant integrase strand transfer activity expressed in Escherichia coli after 60 mins using [32P]-labeled oligonucleotide as a substrate by densitometric analysis in presence of cofactor manganese2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.
AID1075416Ratio of EC50 for Human immunodeficiency virus 1 harboring integrase G118R mutant to EC50 for wild-type Human immunodeficiency virus 12014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.
AID721996Selectivity ratio of IC50 for RAL-resistant HIV1 harboring integrase Q148K mutant to IC50 for wild type HIV1 3B2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles.
AID573974Selectivity index, ratio of CC50 for human MT4 cells to EC50 for Human immunodeficiency virus 1 3B2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID575615Apparent total plasma clearance in healthy human at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID1073322Antiviral activity against HIV-1 harboring integrase E138K/Q148H double mutant relative to wild type HIV12014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID1207351Inhibition of fast sodium current (INa) in HEK293 cells transfected with human Nav1.5 measured using IonWorks Quattro automated patch clamp platform
AID582830Terminal phase half life in HIV-infected human plasma at 800 mg qd for 10 days administered in fasted condition on day 10 by HPLC with fluorescence detector2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.
AID364177Antiviral activity against HIV1 3B in human MT4 cells in presence of 10% heat-activated fetal bovine serum2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID331701Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series.
AID586149Antiviral activity against Human immunodeficiency virus 1 clone 1 harboring integrase E11D, S17T, L45V, M50I, M50T, I72V, L74I, K111T, S119G, T125A relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID587743Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef assessed as level of infection using human HeLaT4 cells pretreated at 100 time EC95 for 24 hrs followed2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID569003Cytotoxicity against human MT4 cells by MTT assay2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
HIV-1 integrase strand-transfer inhibitors: design, synthesis and molecular modeling investigation.
AID1228822Inhibition of HIV-1 integrase assessed as inhibition of strand transfer activity using 32P-labeled DNA as substrate after 1 hr by gel-based assay in presence of Mg2+2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
N-Substituted Quinolinonyl Diketo Acid Derivatives as HIV Integrase Strand Transfer Inhibitors and Their Activity against RNase H Function of Reverse Transcriptase.
AID586173Antiviral activity against Human immunodeficiency virus 1 clone 19 harboring integrase S17N, T124N, T125A, M154I, S195C, V201I mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID586155Antiviral activity against Human immunodeficiency virus 1 clone 13 harboring integrase E11D, S17T, L45V, M50T, I72V, L74I, K111T, S119G, T125A relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID582835Toxicity in HIV-infected human at 800 mg qd for 10 days administered in fasted condition on day 102011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.
AID1361068Cytotoxicity against human MT4 cells after 5 days by MTT assay2018European journal of medicinal chemistry, Jul-15, Volume: 1555-Hydroxypyrido[2,3-b]pyrazin-6(5H)-one derivatives as novel dual inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H and integrase.
AID1126725Inhibition of HIV1 RNase H function of recombinant reverse transcriptase using an 18-nt 3'-fluorescein-labeled RNA annealed to complementary 18-nt 5'-dabsyl-labeled DNA as substrate after 10 mins by fluorescence spectrometer analysis2014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Basic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse transcriptase.
AID541155Selectivity ratio of EC50 for antiviral activity against APV-resistant HIV1 selected after 4 passages to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID586145Antiviral activity against Human immunodeficiency virus 1 clone 15_7 harboring integrase E11D, S17T, L45V, M50T, I72V, L74I, T97A, K111T, S119G, T125A infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect relative to wild t2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID586147Antiviral activity against Human immunodeficiency virus 1 clone 18_13 harboring integrase S17N, T124N, T125A, G140S, M154I, S195C infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID1348220Antiviral activity against HIV1 pNL4-3 infected in HEK293 cells assessed as reduction in viral transcription by measuring decrease in luciferase activity at 1 uM after 20 hrs by luciferase reporter gene assay2017Journal of natural products, 12-22, Volume: 80, Issue:12
Oxazole-Containing Diterpenoids from Cell Cultures of Salvia miltiorrhiza and Their Anti-HIV-1 Activities.
AID533672Tmax in healthy human plasma at 400 mg, po twice a day for 4 days by reverse-phase HPLC-MS method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
AID1237271Ratio of IC50 for HIV-1 integrase-mediated 3' processing and strand transfer reactions in absence of 300 mM sucrose to IC50 for HIV-1 integrase-mediated 3' processing and strand transfer reactions in presence of 300 mM sucrose2015Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15
Investigation on the sucrose binding pocket of HIV-1 Integrase by molecular dynamics and synergy experiments.
AID331699Antiviral activity against HIV1 3B assessed as inhibition of viral-induced cytopathic effect in human MT4 cells2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series.
AID556552Ratio of plasma concentration in patient with hepatic insufficiency to plasma concentration in healthy human at 400 mg, po administered as single dose measured at 12 hrs post dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID586134Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase T97A mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID575624Cmax in healthy human plasma assessed as raltegravir-glucoronide at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID582866Antiviral activity against Human immunodeficiency virus 1 clone 10 harboring integrase R20K, A23V, T97A, T112I, T124N, G193E, V201I, T206S, I220V, D279G mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID562139Cmax in healthy human at 400 mg/kg, po BID for 4 days2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
AID501881Antiviral activity against HIV1 harboring integrase T66I mutant relative to wild type2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Development of 2-pyrrolidinyl-N-methyl pyrimidones as potent and orally bioavailable HIV integrase inhibitors.
AID582826Cmax in HIV-infected human plasma at 800 mg qd for 10 days administered in fasted condition on day 10 by HPLC with fluorescence detector2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.
AID575636AUC (0 to 12 hrs) ratio of drug to raltegravir-glucoronide in healthy human plasma at 400 mg, po Bid for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID582825AUCt in HIV-infected human PBMC at 800 mg qd for 10 days administered in fasted condition on day 10 by LC-MS/MS analysis2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.
AID1222388Inhibition of human recombinant UGT1A1 expressed in HEK293 cells assessed as reduction in bilirubin glucuronidation by LC-MS/MS method2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.
AID541163Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E92Q mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1602241Inhibition of HIV1 reverse transcriptase RNase H expressed in Escherichia coli JM109 using RNA/DNA duplex substrate HTS-12019European journal of medicinal chemistry, Mar-15, Volume: 166Pharmacophore-based design of novel 3-hydroxypyrimidine-2,4-dione subtypes as inhibitors of HIV reverse transcriptase-associated RNase H: Tolerance of a nonflexible linker.
AID676998Selectivity index, ratio of CC50 for human HeLa cells to IC50 for VSV-G pseudotyped HIV1 lentiviral particles2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy.
AID596556Resistant fold, ratio of IC50 for HIV1 integrase N155H mutant strand transfer activity to IC50 for wild type HIV1 integrase strand transfer activity in presence of magnesium2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.
AID541158Selectivity ratio of EC50 for antiviral activity against GS-9160-resistant HIV1 selected after 6 passages to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1152125Therapeutic index, ratio of CC50 for human MT4 cells infected with HIV-1 3B to EC50 for HIV-1 3B infected in human MT4 cells2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.
AID574943Drug level in blood of healthy human at 400 mg/kg administered twice daily measured after 2 to 4 hrs by HPLC2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Raltegravir penetration in seminal plasma of healthy volunteers.
AID1251689Resistance index, ratio of IC50 for antiviral activity against HIV1 expressing integrase Q148K mutant to IC50 for antiviral activity against HIV1 expressing wild type integrase2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors.
AID1605433Selectivity ratio of EC50 for HIV1 NL4-3 harboring G140S/Q148H mutant infected in human MT2 cells to EC50 for HIV1 NL4-3 infected in human MT2 cells2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
Discovery and Optimization of Novel Pyrazolopyrimidines as Potent and Orally Bioavailable Allosteric HIV-1 Integrase Inhibitors.
AID575633Drug level in healthy human urine assessed as raltegravir-glucoronide at 400 mg, po Bid for 1 week measured at 12 to 24 hrs post dose by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID556553Ratio of AUC (0 to infinity) in patient with severe renal insufficiency to AUC (0 to infinity) in healthy human at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID556531Tmax in patient with hepatic insufficiency at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID364212Cmax in dog at 2 mg/kg, po2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID556545Terminal half life in patient with severe renal insufficiency at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID575600Cmax in healthy human plasma at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID584791Toxicity in HIV-seronegative healthy volunteers assessed as occurrence of mild headache at 400 mg, po administered as single dose in presence of 30 ml albuminium, magnesium and simethicone-containg antacid2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
AID587755Antiviral activity against HIV1 NL4-3.Luc in human MDM assessed as infectivity treated for 24 hrs by luciferase assay2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID1847041Inhibition of recombinant His-tagged HIV-1 NL4-3 integrase expressed in Escherichia coli BL21 pLys using GTGTGGAAAATCTCTAGCA/ACTGCTAGAGATTTTCCACAC as DNA substrate incubated for 2 hrs by densitometric analysis2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
Quinolinonyl Non-Diketo Acid Derivatives as Inhibitors of HIV-1 Ribonuclease H and Polymerase Functions of Reverse Transcriptase.
AID582875Antiviral activity against Human immunodeficiency virus 1 clone 18_13 harboring integrase G140S mutant and G140S, Q148H site-directed mutation relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID587753Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef assessed as level of 2 mins magnetic nanopartials-medated infection in human HeLaT4 cells treated for 12011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID508290Antiviral activity against Human immunodeficiency virus 1 clone 4378 harboring integrase E157Q V31I, V32I, S39C, I72V, L101I, K160Q, F181L, V201I, Q216H, A265V mutation transfected in human C8166 cells assessed as decrease in compound susceptibility relat2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector.
AID1152120Inhibition of HIV-1 overall integrase activity using 5'-digoxigenin-labeled GACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGT-3' as substrate after 1 hr by ELISA2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.
AID533685AUC (0 to infinity) in HIV-negative human at 400 mg, po administered as single dose followed by 4 days wash out period followed by efavirenz dosing at 600 mg, po bid for 14 days coadministered with compound at 400 mg, po on day 122008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
AID434441Antiviral activity against HIV1 assessed as inhibition of viral replication by spread cell based assay in presence of 10 %FBS2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center.
AID1191897Drug metabolism assessed as UGT1A9-mediated compound glucuronidation in pooled mixed-gender human liver microsomes at 50 uM preincubated at 37 degC for 3 mins before UDPGA addition by HPLC method2015Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6
A novel molecule with notable activity against multi-drug resistant tuberculosis.
AID575606AUC (0 to tau) in human at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID314172Antiviral activity against HIV1 3B in MT2 cells after 5 days2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Tricyclic HIV integrase inhibitors: potent and orally bioavailable C5-aza analogs.
AID586169Antiviral activity against Human immunodeficiency virus 1 clone 15 harboring integrase S17N, I84I, T124N, T125A, M154I, S195C mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID1075424Cytotoxicity against HOS cells assessed as reduction in ATP level after 48 hrs by luciferase reporter gene assay2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.
AID556530Plasma concentration in patient with hepatic insufficiency at 400 mg, po administered as single dose measured at 12 hrs post dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID1191594Inhibition of HIV-1 integrase after 1 hr by strand transfer activity assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Design and synthesis of N-methylpyrimidone derivatives as HIV-1 integrase inhibitors.
AID575603Plasma concentration in healthy human at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week measured 12 hrs post dose by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID1588920Inhibition of strand transfer activity of HIV1 integrase expressed in Escherichia coli using DNA complexes containing 32P-labeled INT1ST and and non-labeled INT22019Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17
Design, synthesis and biological evaluation of 3-hydroxyquinazoline-2,4(1H,3H)-diones as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and integrase.
AID556532Primary phase half life in patient with hepatic insufficiency at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID569001Inhibition of HIV-1 integrase strand transfer activity after 1 hr by ELISA2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
HIV-1 integrase strand-transfer inhibitors: design, synthesis and molecular modeling investigation.
AID562126Terminal half life in healthy human at 400 mg/kg, po administered as single dose in presence of 600 mg/kg, po rifampin2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
AID413254Ratio of IC50 for HIV1 integrase 3'-end processing activity to IC50 for HIV1 integrase strand transfer activity2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.
AID525113Antiviral activity against HIV 1 NL4.3 integrase E92Q mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID573972Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of viral replication2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID1193109Therapeutic index, ratio of CC50 for cat FL-4 cells to EC50 for Feline immunodeficiency virus infected in cat FL-4 cells2015Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6
Novel fused tetrathiocines as antivirals that target the nucleocapsid zinc finger containing protein of the feline immunodeficiency virus (FIV) as a model of HIV infection.
AID364242Antiviral activity against HIV1 with integrase T66I mutation by single cycle infectivity assay in presence of 10%FBS2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID501882Antiviral activity against HIV1 harboring integrase V151I mutant relative to wild type2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Development of 2-pyrrolidinyl-N-methyl pyrimidones as potent and orally bioavailable HIV integrase inhibitors.
AID533883AUC (0 to infinity) in HIV-negative human at 400 mg, po administered as single dose2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
AID575618Cmax in healthy human plasma assessed as raltegravir-glucoronide at 400 mg, po Bid for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID584781Cmax in HIV-seronegative healthy volunteers at 400 mg, po administered as single dose by LC-MS/MS2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
AID1152123Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect by MTT assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.
AID541114Antiviral activity against HIV1 3B infected in human MT-4 cells by two fold dilution method in presence of 10% FBS2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID533691AUC (0 to infinity) in HIV-negative human at 400 mg, po administered as single dose followed by 4 days wash out period followed by ritonavir dosing at 100 mg, po bid for 16 days coadministered with compound at 400 mg, po on day 142008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
AID1264518Cytotoxicity against human Jurkat cells after 48 to 72 hrs by MTT assay2015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Design, Synthesis, and Biological Evaluation of 1,2-Dihydroisoquinolines as HIV-1 Integrase Inhibitors.
AID760005Inhibition of HIV1 integrase overall inhibition using 5'-digoxigenin-labeled 5'-GACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGT-3' as substrate after 1 hr by ELISA2013ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7
4-Substituted 2-Hydroxyisoquinoline-1,3(2H,4H)-diones as a Novel Class of HIV-1 Integrase Inhibitors.
AID574947Drug level in plasma of healthy human2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Raltegravir penetration in seminal plasma of healthy volunteers.
AID525102Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID573973Cytotoxicity against human MT4 cells by MTT assay2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID575628AUC (0 to12 hrs) in healthy human assessed as raltegravir-glucoronide at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID364189Binding affinity to human ERG2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID1073331Antiviral activity against HIV-1 harboring integrase Y143C mutant relative to wild type HIV12014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID1597907Acute cytotoxicity against cat CRFK cells assessed as decrease in cell viability at 10 uM measured after 24 hrs by MTT assay relative to control2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Novel epidithiodiketopiperazines as anti-viral zinc ejectors of the Feline Immunodeficiency Virus (FIV) nucleocapsid protein as a model for HIV infection.
AID562346Antiviral activity against HIV1 N-19 harboring integrase D10E, E11D, D25E, V31I, I113V, S119G, A124N, V151I, V201I, N232D mutant gene infected in human TZM-bl cells assessed as beta-galactosidase expression after 48 hrs by microplate luminometry relative 2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors.
AID556534AUC (0 to infinity) in healthy human at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID584786Ratio of AUC (0 to infinity) in HIV-seronegative healthy volunteers at 400 mg, po administered as single dose in presence of albuminium, magnesium and simethicone-containg antacid to AUC (0 to 12 hrs) in HIV-seronegative healthy volunteers at 400 mg, po a2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
AID1152133Resistance ratio of EC50 for raltegravir-resistant HIV1 harboring integrase N155H mutant to EC50 for wild type HIV12014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.
AID1207570Inhibition of long-lasting type calcium current (hICa) in Chinese Hamster Ovary (CHO) cells expressing hCav1.2 measured using IonWorks Quattro automated patch clamp platform
AID364180Inhibition of HIV reverse transcriptase2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID596561Resistant fold, ratio of EC50 for HIV1 harboring integrase N155H mutant to EC50 for HIV1 harboring wild-type integrase2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.
AID1736354Antiviral activity against VSVG/wild-type HIV-1 infected in human HEK 293T cells assessed as time during which compound exhibits 50% virologic failure at 1 uM treated at post-viral infection and measured at 48 hrs post-infection by luciferase reporter gen
AID1602243Inhibition of HIV1 integrase strand transfer activity using 5'-biotinylated oligonucleotide as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins2019European journal of medicinal chemistry, Mar-15, Volume: 166Pharmacophore-based design of novel 3-hydroxypyrimidine-2,4-dione subtypes as inhibitors of HIV reverse transcriptase-associated RNase H: Tolerance of a nonflexible linker.
AID1450146Antiviral activity against HIV-1 NL4.3 infected in human TZM-b1 cells pretreated for 1 hr followed by viral infection measured after 2 days by CPRG assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
One drug for two targets: Biological evaluation of antiretroviral agents endowed with antiproliferative activity.
AID364198Plasma clearance in rhesus monkey at 1 mg/kg, iv2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID591590Fold resistance, ratio of EC50 for raltegravir-resistant Human immunodeficiency virus 1 8070-2 expressing integrase G140S/Q148H mutant to EC50 for raltegravir-resistant Human immunodeficiency virus 1 8070-2 expressing wild-type integrase2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integrase.
AID575635Renal clearance in healthy human assessed as raltegravir-glucoronide at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID1056584Antiviral activity against wild-type HIV-1 infected in HEK293T cells co-transfected with VSVG protein assessed as time required for 50% failure of viral replication at 10 uM by luciferase reporter gene assay2013Journal of natural products, Dec-27, Volume: 76, Issue:12
Phenylspirodrimanes with anti-HIV activity from the sponge-derived fungus Stachybotrys chartarum MXH-X73.
AID562140Tmax in healthy human at 400 mg/kg, po BID for 4 days2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
AID496470Antiviral activity against HIV1-infected in human assessed as decrease in plasma viral RNA level measured after 9 hrs post dose2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.
AID1152127Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of p24 antigen production by measuring time delay in loss of compound activity at 50 to 100 times EC50 by ELISA2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.
AID575637AUC (0 to 12 hrs) ratio of drug to raltegravir-glucoronide in healthy human plasma at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID586137Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase V151I mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID595928Inhibition of HIV1 recombinant integrase strand transfer activity expressed in Escherichia coli after 30 mins using [32P]-labeled oligonucleotide as a substrate by densitometric analysis2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.
AID1301001Selectivity ratio of EC50 for raltegravir resistant HIV1 harboring integrase G140S/Q148H double mutant infected in human MT4 cells to EC50 for wild type HIV1 infected in human MT4 cells2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID721993Selectivity ratio of IC50 for RAL-resistant HIV1 harboring integrase N155H mutant to IC50 for wild type HIV1 3B2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles.
AID525104Antiviral activity against HIV 1 3B harboring integrase E92Q S230N double mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 20 passages in presence of compound2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID1365354Selectivity index, ratio of CC50 for cytotoxic activity against mock-infected human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
1-Hydroxypyrido[2,3-d]pyrimidin-2(1H)-ones as novel selective HIV integrase inhibitors obtained via privileged substructure-based compound libraries.
AID1588926Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay2019Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17
Design, synthesis and biological evaluation of 3-hydroxyquinazoline-2,4(1H,3H)-diones as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and integrase.
AID634129Antiviral activity against Human immunodeficiency virus 1 infected in human TZM-bl cells assessed as inhibition of viral replication after 48 hrs by inverted microscopic analysis2012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Design and synthesis of novel β-diketo derivatives as HIV-1 integrase inhibitors.
AID1053408Antiviral activity against HIV1 3B/LAI infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect measured survival after 5 days by MTT assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
6-(1-Benzyl-1H-pyrrol-2-yl)-2,4-dioxo-5-hexenoic acids as dual inhibitors of recombinant HIV-1 integrase and ribonuclease H, synthesized by a parallel synthesis approach.
AID364182Inhibition of human DNA polymerase alpha2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID707909Binding affinity to CCR12012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Chemokine receptor antagonists.
AID1073320Antiviral activity against HIV-1 harboring integrase G140S/Q148H double mutant relative to wild type HIV12014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID562349Antiviral activity against HIV1 G-8 harboring integrase D10E, L101I, S119T, A124T, M154L, V201I, N232D, S283G mutant gene infected in human TZM-bl cells assessed as beta-galactosidase expression after 48 hrs by microplate luminometry relative to HIV1 R7/32009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors.
AID1565229Inhibition of His-tagged HIV-1 integrase interaction with HIV-1 FLAG-tagged LEDGF/p75 expressed in Escherichia coli BL21(DE3) cells at 100 uM incubated for 30 mins followed by LEDGF addition measured after 4 hrs by HTRF assay relative to control2019European journal of medicinal chemistry, Nov-15, Volume: 182Chromenone derivatives as a versatile scaffold with dual mode of inhibition of HIV-1 reverse transcriptase-associated Ribonuclease H function and integrase activity.
AID1207322Inhibition of fast sodium current (INa) in Chinese Hamster Ovary (CHO) K1 cells transfected with human Nav1.5 measured using IonWorks Quattro automated patch clamp platform
AID582827Cmax in HIV-infected human PBMC at 800 mg qd for 10 days administered in fasted condition on day 10 by LC-MS/MS analysis2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.
AID586170Antiviral activity against Human immunodeficiency virus 1 clone 16 harboring integrase S17N, T124N, T125A, M154I, S195C, V201I mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID331698Inhibition of HIV1 integrase strand transfer activity2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series.
AID634131Cytotoxicity against human TZM-bl cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Design and synthesis of novel β-diketo derivatives as HIV-1 integrase inhibitors.
AID533885Terminal half life in HIV-negative human at 400 mg, po administered as single dose followed by 4 days wash out period followed by efavirenz dosing at 600 mg, po bid for 14 days coadministered with compound at 400 mg, po on day 122008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
AID1406294Antiviral activity against HIV1 infected in CD4/CXCR4/CCR5 expressing human P4R5 MAGI cells preincubated with cells for 24 hrs followed by viral infection measured after 48 hrs by beta-galactosidase reporter gene assay2018European journal of medicinal chemistry, Aug-05, Volume: 1566-Arylthio-3-hydroxypyrimidine-2,4-diones potently inhibited HIV reverse transcriptase-associated RNase H with antiviral activity.
AID584795Terminal half life in human at 400 mg BID2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
AID1073314Antiviral activity against HIV-1 harboring integrase E92V mutant relative to wild type HIV12014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID562121Cmin in healthy human at 400 mg/kg, po administered as single dose after 12 hrs in presence of 600 mg/kg, po rifampin2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
AID575623AUC (12 to 24 hrs) in healthy human assessed as raltegravir-glucoronide at 400 mg, po Bid for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID575604AUC (0 to12 hrs) in healthy human at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID541106Antiviral activity against HIV1 infected in human assessed as decrease log10 in HIV RNA copies per ml from baseline at 100 to 600 mg BID measured on day 102009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID562351Antiviral activity against HIV1 K-2 harboring integrase D10E, R20K, I113V, A124T, K188R, V201I, T206S, N232D, D278G mutant gene infected in human TZM-bl cells assessed as beta-galactosidase expression after 48 hrs by microplate luminometry relative to HIV2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors.
AID541173Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E138K and Q148K mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1207505Inhibition of rapid delayed inward rectifying potassium current (IKr) in Chinese hamster ovary (CHO) cells stable expressing hERG measured using IonWorks Barracuda automated patch clamp platform
AID582868Antiviral activity against Human immunodeficiency virus 1 clone 14 harboring integrase R20K, A23V, T124N, I141V, K156N, G193E, V201I, T206S, I220V, D279G mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID417573Inhibition of HIV integrase strand transfer activity2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Tricyclic HIV integrase inhibitors V. SAR studies on the benzyl moiety.
AID586136Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase G140S mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID634132Therapeutic index, ratio of CC50 for human TZM-bl cells to EC50 for Human immunodeficiency virus 12012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Design and synthesis of novel β-diketo derivatives as HIV-1 integrase inhibitors.
AID1635805Antiviral activity against HIV1 infected in human P4R5 cells assessed as reduction of virus replication preincubated with cells for 24 hrs followed by viral infection for 48 hrs by 4-methylumbelliferylgalactoside-based MAGI assay2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H.
AID586159Antiviral activity against Human immunodeficiency virus 1 clone 1 harboring integrase S17N, I84I, T124N, T125A, M154I, S195C mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID501885Antiviral activity against HIV1 harboring integrase T66I and M154I double mutant relative to wild type2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Development of 2-pyrrolidinyl-N-methyl pyrimidones as potent and orally bioavailable HIV integrase inhibitors.
AID1060855Antiviral activity against HIV1 NL4.3 infected in human TZM-bl cells expressing CXCR4-tropic incubated for 1 hr prior to infection measured after 48 hrs by luciferase reporter gene assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis, anti-HIV activity, integrase enzyme inhibition and molecular modeling of catechol, hydroquinone and quinol labdane analogs.
AID1597909Antiviral activity against FIV infected in cat FL-4 cells assessed as reduction in viral RNA level measured after 7 days by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Novel epidithiodiketopiperazines as anti-viral zinc ejectors of the Feline Immunodeficiency Virus (FIV) nucleocapsid protein as a model for HIV infection.
AID364201Volume of distribution in rhesus monkey at 5 mg/kg, iv2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID1073307Binding affinity to HIV integrase assessed as dissociation half life2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID586175Antiviral activity against Human immunodeficiency virus 1 clone 3 harboring integrase R20K, A23V, T124N, I141V, G193E, V201I, T206S, I220V, M275Vmutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID1251686Resistance index, ratio of IC50 for antiviral activity against HIV1 expressing integrase E92Q mutant to IC50 for antiviral activity against HIV1 expressing wild type integrase2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors.
AID1311346Inhibition of recombinant HIV1 subtype C integrase strand transfer activity assessed as residual activity at 20 uM preincubated for 45 mins followed by double-stranded FITC-labelled DNA addition measured after 60 mins relative to control2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Synthesis and evaluation of substituted 4-(N-benzylamino)cinnamate esters as potential anti-cancer agents and HIV-1 integrase inhibitors.
AID541150Selectivity ratio of EC50 for antiviral activity against 3TC-resistant HIV1 selected after 4 passages to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID575622AUC (0 to12 hrs) in healthy human assessed as raltegravir-glucoronide at 400 mg, po Bid for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID591587Ratio of IC50 for Human immunodeficiency virus 1 NL4-3 integrase G140S/Q148H mutant to IC50 for wild-type Human immunodeficiency virus 1 NL4-3 integrase2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integrase.
AID584775Tmax in HIV-seronegative healthy volunteers at 400 mg, po administered as single dose by LC-MS/MS2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
AID364217AUC in Sprague-Dawley rat at 3 mg/kg, po2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID575595Plasma concentration in healthy human at 400 mg, po Bid for 1 week measured 12 hrs post dose by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID556548Renal clearance in patient with severe renal insufficiency at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID573995Ratio of EC50 for Human immunodeficiency virus 1 3B to EC50 for L-708,906-resistant Human immunodeficiency virus harboring T66I, L74M and S230R mutations in integrase2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID541160Selectivity ratio of EC50 for antiviral activity against GS-9160-resistant HIV1 selected after 9 passages to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1060852Inhibition of HIV1 integrase at 50 uM2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis, anti-HIV activity, integrase enzyme inhibition and molecular modeling of catechol, hydroquinone and quinol labdane analogs.
AID496469Antiviral activity against HIV1-infected in human assessed as decrease in semen viral RNA level measured after 5 hrs post dose2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.
AID1075422Antiviral activity against Human immunodeficiency virus 1 harboring integrase N155H mutant infected in HOS cells preincubated for 3 hrs followed by viral infection measured after 48 hrs by luciferase reporter gene assay2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.
AID582867Antiviral activity against Human immunodeficiency virus 1 clone 13 harboring integrase R20K, A23V, T124N, G193E, V201I, T206S, I268V, I220V mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID584777Drug level in HIV-seronegative healthy volunteers blood at 400 mg, po administered as single dose after 12 hrs by LC-MS/MS in presence of albuminium, magnesium and simethicone-containg antacid2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
AID1199594Inhibition of HIV-1 integrase strand transfer activity by gel-based assay2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Structure-activity relationship of pyrrolyl diketo acid derivatives as dual inhibitors of HIV-1 integrase and reverse transcriptase ribonuclease H domain.
AID533669AUC (0 to 12 hrs) in healthy human plasma at 400 mg, po twice a day for 4 days coadministered with 200mg of etravirine twice a day for 4 days by reverse-phase HPLC-MS method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
AID525107Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID586146Antiviral activity against Human immunodeficiency virus 1 clone 15_19 harboring integrase E11D, S17T, L45V, M50T, I72V, L74I, T97A, K111T, S119G, T125A infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect relative to wild 2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID1660997Antileishmanial activity against Leishmania donovani amastigotes infected in human THP1 cells incubated for 96 hrs2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent
AID364187Inhibition of CYP2D62008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID584793Ratio of Cmax in HIV-infected patients at 400 mg, po treated after 2 hrs administration of 20 mg proton pump inhibitor omeprazole to Cmax in HIV-infected patients at 400 mg, po2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
AID634130Inhibition of Human immunodeficiency virus 1 integrase-mediated strand transfer activity after 1 hr2012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Design and synthesis of novel β-diketo derivatives as HIV-1 integrase inhibitors.
AID575596AUC (0 to12 hrs) in healthy human at 400 mg, po Bid for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID541165Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E138K mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID587741Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef infected in human HeLa-T4 cells assessed as time required to 50% inhibition of infection at 100 times E2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID364220AUC in dog at 2 mg/kg, po2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID533693Terminal half life in HIV-negative human at 400 mg, po administered as single dose2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
AID497134Cytotoxicity against human MT4 cells by MTT assay2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
New chloro,fluorobenzylindole derivatives as integrase strand-transfer inhibitors (INSTIs) and their mode of action.
AID533668AUC (0 to 12 hrs) in healthy human plasma at 400 mg, po twice a day for 4 days by reverse-phase HPLC-MS method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
AID586151Antiviral activity against Human immunodeficiency virus 1 clone 7 harboring integrase E11D, S17T, L45V, M50T, I72V, L74I, K111T, T125A relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID562343Antiviral activity against HIV1 A-6 harboring integrase D10E, V72I, A124T, M154I, R199K, V201I, N232D mutant gene infected in human TZM-bl cells assessed as beta-galactosidase expression after 48 hrs by microplate luminometry relative to HIV1 R7/3 express2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors.
AID1126723Inhibition of HIV1 integrase 3'-processing activity by gel-based assays2014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Basic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse transcriptase.
AID556536Plasma concentration in healthy human at 400 mg, po administered as single dose measured at 12 hrs post dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID575630Drug level in healthy human urine assessed as raltegravir-glucoronide at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week measured at 12 to 24 hrs post dose by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID314173Antiviral activity against HIV in MT2 cells in presence of 35 mg/mL human serum albumin2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Tricyclic HIV integrase inhibitors: potent and orally bioavailable C5-aza analogs.
AID702897Inhibition of wild type HIV1 3B infected in human MT4 cells using cells pre-incubated with compound for 1 hr measured 4 days post viral infection in presence of 20 mg/ml HSA by MTT assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Carbamoyl pyridone HIV-1 integrase inhibitors. 1. Molecular design and establishment of an advanced two-metal binding pharmacophore.
AID413252Inhibition of HIV1 integrase 3'-end processing activity2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.
AID1602244Antiviral activity against HIV-1 infected in human P4R5 cells assessed as reduction in viral replication preincubated for 24 hrs followed by viral infection and measured after 48 hrs by MAGI assay2019European journal of medicinal chemistry, Mar-15, Volume: 166Pharmacophore-based design of novel 3-hydroxypyrimidine-2,4-dione subtypes as inhibitors of HIV reverse transcriptase-associated RNase H: Tolerance of a nonflexible linker.
AID575601Cmin in healthy human plasma at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID533882Cmax in HIV-negative human at 400 mg, po administered as single dose2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
AID586162Antiviral activity against Human immunodeficiency virus 1 clone 4 harboring integrase S17N, S57G, I84I, T124N, T125A, M154I, S195C mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID1073333Antiviral activity against HIV-1 harboring integrase E138K mutant relative to wild type HIV12014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID1483415Inhibition of HIV integrase strand transfer activity expressed in Escherichia coli BL21 (DE3) using 5' biotin ATGTGGAAAATCTCTAGCA primer annealed with ACTGCTAGAGATTTTCCACAT 3' Cy5 template preincubated for 10 mins followed by primer/template addition meas2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Double-Winged 3-Hydroxypyrimidine-2,4-diones: Potent and Selective Inhibition against HIV-1 RNase H with Significant Antiviral Activity.
AID575614Apparent clearance of oral drug in healthy human assessed as drug excreted unchanged at 400 mg, po Bid for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID1597910Therapeutic index, ratio of CC50 for cat FL-4 cells to EC50 for antiviral activity against FIV infected in cat FL-4 cells2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Novel epidithiodiketopiperazines as anti-viral zinc ejectors of the Feline Immunodeficiency Virus (FIV) nucleocapsid protein as a model for HIV infection.
AID575631AUC (12 to 24 hrs) in healthy human assessed as raltegravir-glucoronide at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID1565226Inhibition of multimerization of of His and Flag-tagged HIV-1 integrase expressed in Escherichia coli BL21(DE3) cells after 2.5 hrs by HTRF assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Chromenone derivatives as a versatile scaffold with dual mode of inhibition of HIV-1 reverse transcriptase-associated Ribonuclease H function and integrase activity.
AID1251684Antiviral activity against HIV1 infected in human MT4 cells expressing GFP incubated for 48 to 72 hrs in absence of 50% normal human serum by multiple round viral replication kinetics assay2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors.
AID1635802Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as reduction of virus-induced cytopathic effect after 6 days by MTS assay2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H.
AID533690Cmax in HIV-negative human at 400 mg, po administered as single dose followed by 4 days wash out period followed by ritonavir dosing at 100 mg, po bid for 16 days coadministered with compound at 400 mg, po on day 142008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
AID575627Plasma concentration in healthy human assessed as raltegravir-glucoronide at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week measured 12 hrs post dose by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID1060856Cytotoxicity against human TZM-bl cells assessed as cell viability after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis, anti-HIV activity, integrase enzyme inhibition and molecular modeling of catechol, hydroquinone and quinol labdane analogs.
AID1073319Antiviral activity against HIV-1 harboring integrase G140S/Q148K double mutant relative to wild type HIV12014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID575617Apparent clearance of oral drug in healthy human assessed as drug excreted unchanged at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID417574Antiviral activity against HIV1 3B infected in human MT2 cells after 5 days by chemiluminescence in presence of fetal bovine serum2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Tricyclic HIV integrase inhibitors V. SAR studies on the benzyl moiety.
AID760006Inhibition of strand transfer activity of HIV1 integrase using pre-cleaved oligonucleotide as substrate after 1 hr by ELISA2013ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7
4-Substituted 2-Hydroxyisoquinoline-1,3(2H,4H)-diones as a Novel Class of HIV-1 Integrase Inhibitors.
AID1588917Inhibition of HIV integrase strand transfer activity2019Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17
Design, synthesis and biological evaluation of 3-hydroxyquinazoline-2,4(1H,3H)-diones as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and integrase.
AID586139Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase K156N mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID1361067Antiviral activity against Human immunodeficiency virus 1 3B infected in MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post infection by MTT assay2018European journal of medicinal chemistry, Jul-15, Volume: 1555-Hydroxypyrido[2,3-b]pyrazin-6(5H)-one derivatives as novel dual inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H and integrase.
AID556540AUC (0 to infinity) in patient with severe renal insufficiency at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID1073318Antiviral activity against HIV-1 harboring integrase T97A/Y143C double mutant relative to wild type HIV12014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID533670Cmax in healthy human plasma at 400 mg, po twice a day for 4 days by reverse-phase HPLC-MS method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
AID541108Inhibition of HIV1 integrase strand transfer activity2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID676995Selectivity index, ratio of CC50 for human HeLa cells to IC50 for Plasmodium falciparum 3D7 ring stage cells2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy.
AID533673Tmax in healthy human plasma at 400 mg, po twice a day for 4 days coadministered with 200mg of etravirine twice a day for 4 days by reverse-phase HPLC-MS method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
AID1073326Antiviral activity against HIV-1 harboring integrase N155H mutant relative to wild type HIV12014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID586161Antiviral activity against Human immunodeficiency virus 1 clone 3 harboring integrase S17N, I84I, T124N, T125A, M154I, S195C mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID541115Cytotoxicity against human MT4 cells infected with HIV1 3B by three fold dilution method in presence of 10% FBS2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID501887Antiviral activity against HIV1 harboring integrase T125K and F12Y double mutant relative to wild type2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Development of 2-pyrrolidinyl-N-methyl pyrimidones as potent and orally bioavailable HIV integrase inhibitors.
AID364219AUC in rhesus monkey at 10 mg/kg, po2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID1565224Inhibition of subunit exchanging activity of His and Flag-tagged HIV-1 integrase expressed in Escherichia coli BL21(DE3) cells after 2.5 hrs by HTRF assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Chromenone derivatives as a versatile scaffold with dual mode of inhibition of HIV-1 reverse transcriptase-associated Ribonuclease H function and integrase activity.
AID434451Antiviral activity against HIV1 assessed as inhibition of viral replication by spread cell based assay in presence of 50 %NHS2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center.
AID562135Cmax in healthy human at 800 mg/kg, po BID for 14 days in presence of 600 mg/kg, po rifampin2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
AID702892Inhibition of wild type HIV1 3B infected in human MT4 cells using cells pre-incubated with compound for 1 hr measured 4 days post viral infection by MTT assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Carbamoyl pyridone HIV-1 integrase inhibitors. 1. Molecular design and establishment of an advanced two-metal binding pharmacophore.
AID1365353Cytotoxic activity against mock-infected human MT4 cellls assessed as reduction in cell viability by MTT assay2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
1-Hydroxypyrido[2,3-d]pyrimidin-2(1H)-ones as novel selective HIV integrase inhibitors obtained via privileged substructure-based compound libraries.
AID1251688Resistance index, ratio of IC50 for antiviral activity against HIV1 expressing integrase Q148R mutant to IC50 for antiviral activity against HIV1 expressing wild type integrase2015Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20
Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors.
AID586143Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase S230N mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID1300995Antiviral activity against HIV1 3B infected in human MT4 cells at 50 to 100 times antiviral EC50 added 1 to 25 hrs post infection assessed as time required for loss of inhibition of viral replication measured at 30 hrs post infection by p24 ELISA method2016European journal of medicinal chemistry, Jul-19, Volume: 1172-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.
AID556542Plasma concentration in patient with severe renal insufficiency at 400 mg, po administered as single dose measured at 12 hrs post dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID541109Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID364191Primary phase half life in Sprague-Dawley rat at 3 mg/kg, iv2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID1199597Selectivity index, ratio of CC50 for HeLa-CD4-LTR-beta-gal cells to EC50 for HIV-1 3B2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Structure-activity relationship of pyrrolyl diketo acid derivatives as dual inhibitors of HIV-1 integrase and reverse transcriptase ribonuclease H domain.
AID556539Terminal half life in healthy human at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID1152118Resistance ratio of EC50 for raltegravir-resistant HIV1 harboring integrase E92Q mutant to EC50 for wild type HIV12014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.
AID584776Tmax in HIV-seronegative healthy volunteers at 400 mg, po administered as single dose by LC-MS/MS in presence of albuminium, magnesium and simethicone-containg antacid2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
AID1075423Antiviral activity against Human immunodeficiency virus 1 harboring integrase Y143R mutant infected in HOS cells preincubated for 3 hrs followed by viral infection measured after 48 hrs by luciferase reporter gene assay2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.
AID1126722Inhibition of HIV1 integrase strand transfer activity by gel-based assay2014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Basic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse transcriptase.
AID587738Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef infected in human HeLa-T4 cells assessed as luciferase activity after 48 hrs by exogenous RT assay2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID585979Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID562127Cmin in healthy human at 400 mg/kg, po administered as single dose after 12 hrs2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
AID556529Cmax in patient with hepatic insufficiency at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID1565225Inhibition of subunit exchanging activity of His and Flag-tagged HIV-1 integrase expressed in Escherichia coli BL21(DE3) cells at 100 uM after 2.5 hrs by HTRF assay relative to control2019European journal of medicinal chemistry, Nov-15, Volume: 182Chromenone derivatives as a versatile scaffold with dual mode of inhibition of HIV-1 reverse transcriptase-associated Ribonuclease H function and integrase activity.
AID1380353Lipophilicity, log D of the compound at pH 7.4 by chromatographic method2018Journal of medicinal chemistry, 08-09, Volume: 61, Issue:15
Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations.
AID364200Terminal half life in rhesus monkey at 1 mg/kg, iv2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID541175Selectivity ratio of EC50 for antiviral activity against HIV1 harboring G140S and Q148H mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID582873Antiviral activity against Human immunodeficiency virus 1 clone 15_19 harboring integrase T97A mutant and T97A, Y143R site-directed mutation relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID575610Drug level in healthy human urine at 400 mg, po Bid for 1 week measured at 0-12 hrs post dose by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID508284Antiviral activity against Human immunodeficiency virus 1 clone 4736_4 harboring integrase N155H, E92Q and D6E, S17N, R20K, D25E, S39C, L45V, L101I, T124A, K160T, V201I, K211R, D288N mutation transfected in human C8166 cells assessed as decrease in compou2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector.
AID541116Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B in presence of 10% FBS2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1365351Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral-induced cytopathic effect by MTT assay2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
1-Hydroxypyrido[2,3-d]pyrimidin-2(1H)-ones as novel selective HIV integrase inhibitors obtained via privileged substructure-based compound libraries.
AID1126730Selectivity index, ratio of CC50 for human HeLa cells expressing CD4-LTR-beta-gal to EC50 for HIV1 3B2014Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8
Basic quinolinonyl diketo acid derivatives as inhibitors of HIV integrase and their activity against RNase H function of reverse transcriptase.
AID1503542Cytotoxicity in human CEM-SS cells assessed as reduction in cell viability by MTS assay2017European journal of medicinal chemistry, Dec-01, Volume: 141Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H.
AID1605427Antiviral activity against HIV1 NL4-3 infected in human MT2 cells measured after 3 to 4 days by luciferase reporter gene assay2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
Discovery and Optimization of Novel Pyrazolopyrimidines as Potent and Orally Bioavailable Allosteric HIV-1 Integrase Inhibitors.
AID1053411Inhibition of strand transfer activity of recombinant HIV1 integrase using 5'-end-labeled 21-mer double-stranded DNA as substrate after 60 mins by electrochemiluminescent plate-based assay2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
6-(1-Benzyl-1H-pyrrol-2-yl)-2,4-dioxo-5-hexenoic acids as dual inhibitors of recombinant HIV-1 integrase and ribonuclease H, synthesized by a parallel synthesis approach.
AID574940Drug level in blood of healthy human at 400 mg/kg administered twice daily measured on day 5 by HPLC2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Raltegravir penetration in seminal plasma of healthy volunteers.
AID1199596Cytotoxicity against human HeLa expressing CD4 and integrated copy of HIV-1 LTR-driven beta-D-galactosidase reporter cells after 24 hrs by luminescence assay2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Structure-activity relationship of pyrrolyl diketo acid derivatives as dual inhibitors of HIV-1 integrase and reverse transcriptase ribonuclease H domain.
AID417576Ratio of EC50 for HIV1 3B in presence of human serum proteins to EC50 for HIV1 3B in presence of fetal bovine serum2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Tricyclic HIV integrase inhibitors V. SAR studies on the benzyl moiety.
AID364183Inhibition of human DNA polymerase beta2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID541152Selectivity ratio of EC50 for antiviral activity against EFV-resistant HIV1 selected after 3 passages to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID562124Tmax in healthy human at 400 mg/kg, po administered as single dose in presence of 600 mg/kg, po rifampin2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
AID525111Antiviral activity against HIV 1 NL4.3 assessed as inhibition of virus-induced cytopathic effect by MTT assay2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID1483413Inhibition of recombinant full length HIV1 reverse transcriptase RNase H domain using RNA/DNA duplex substrate HTS1 assessed as reduction in internal cleavage of RNA strand by fluoresence assay2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Double-Winged 3-Hydroxypyrimidine-2,4-diones: Potent and Selective Inhibition against HIV-1 RNase H with Significant Antiviral Activity.
AID533667Trough drug concentration at 12 hrs in healthy human plasma at 400 mg, po twice a day for 4 days coadministered with 200mg of etravirine twice a day for 4 days by reverse-phase HPLC-MS method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
AID556551Ratio of Cmax in patient with hepatic insufficiency to Cmax in healthy human at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID562128AUC (0 to infinity) in healthy human at 400 mg/kg, po administered as single dose2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
AID525114Antiviral activity against HIV 1 NL4.3 integrase S230N mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID1552575Binding affinity to recombinant wild-type full length HIV1 reverse transcriptase p66/p51 expressed in Escherichia coli by biolayer interferometry2019Bioorganic & medicinal chemistry, 08-15, Volume: 27, Issue:16
Biological evaluation of molecules of the azaBINOL class as antiviral agents: Inhibition of HIV-1 RNase H activity by 7-isopropoxy-8-(naphth-1-yl)quinoline.
AID1725450Inhibition of HIV1 integrase assessed as reduction in LEDGF-independent integration pre-incubated for 1 hr before addition of DNA donor and acceptor substrate and measured after 90 mins by HTRF assay2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Development of a Raltegravir-based Photoaffinity-Labeled Probe for Human Immunodeficiency Virus-1 Integrase Capture.
AID587740Selectivity index, ratio of CC50 for human HeLa-T4 cells to EC50 for single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID501883Antiviral activity against HIV1 harboring integrase F12Y mutant relative to wild type2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Development of 2-pyrrolidinyl-N-methyl pyrimidones as potent and orally bioavailable HIV integrase inhibitors.
AID582874Antiviral activity against Human immunodeficiency virus 1 clone 15_12 harboring integrase Y143R site-directed mutation relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID596560Resistant fold, ratio of EC50 for HIV1 harboring integrase Y143R mutant to EC50 for HIV1 harboring wild-type integrase2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.
AID1199595Antiviral activity against HIV-1 3B infected in human HeLa-CD4-LTR-beta-gal cells after 1 day by spectroscopic analysis2015Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4
Structure-activity relationship of pyrrolyl diketo acid derivatives as dual inhibitors of HIV-1 integrase and reverse transcriptase ribonuclease H domain.
AID375393Inhibition of HIV1 integrase 3'-processing activity using labelled oligonucleotide substrate by ELISA2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration of novel thiobarbituric acid-, rhodanine- and thiohydantoin-based HIV-1 integrase inhibitors.
AID575632Drug level in healthy human urine assessed as raltegravir-glucoronide at 400 mg, po Bid for 1 week measured at 0-12 hrs post dose by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID587750Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef assessed as level of 2 mins magnetic nanopartials-medated residual infection in human HeLaT4 cells trea2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID525105Antiviral activity against HIV 1 3B harboring integrase L34M mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 40 passages in presence of compound2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID1661000Kinetic aqueous solubility of the compound2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent
AID1152846Cytotoxicity against cat CRFK cells assessed as cell viability after 7 days by MTT assay2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Evaluation of the antiviral efficacy of bis[1,2]dithiolo[1,4]thiazines and bis[1,2]dithiolopyrrole derivatives against the nucelocapsid protein of the Feline Immunodeficiency Virus (FIV) as a model for HIV infection.
AID591588Ratio of IC50 for Human immunodeficiency virus 1 NL4-3 integrase Y143R mutant to IC50 for wild-type Human immunodeficiency virus 1 NL4-3 integrase2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integrase.
AID541151Selectivity ratio of EC50 for antiviral activity against 3TC-resistant HIV1 selected after 8 passages to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID584789Ratio of drug level in HIV-seronegative healthy volunteers blood at 400 mg after 12 hrs, po administered as single dose in presence of albuminium, magnesium and simethicone-containg antacid to drug level in HIV-seronegative healthy volunteers blood at 4002010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
AID584780AUC (0 to infinity) in HIV-seronegative healthy volunteers at 400 mg, po administered as single dose by LC-MS/MS in presence of albuminium, magnesium and simethicone-containg antacid2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
AID586160Antiviral activity against Human immunodeficiency virus 1 clone 2 harboring integrase S17N, I84I, T124N, T125A, M154I, E157K, S195C mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID541161Selectivity ratio of EC50 for antiviral activity against HIV1 harboring T66I mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1503547Antiviral activity against HIV1 infected in human P4R5 cells assessed as reduction in viral infection preincubated with cells for 24 hrs followed by viral infection measured after 48 hrs by fluorescence based beta-galactosidase reporter gene based MAGI as2017European journal of medicinal chemistry, Dec-01, Volume: 141Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H.
AID541107Antiviral activity against HIV1 infected in human assessed as decrease in log10 HIV RNA copies per ml from baseline at 50 mg SID after 10 days2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID364186Inhibition of CYP2C92008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID364244Antiviral activity against HIV1 with integrase F121Y mutation by single cycle infectivity assay in presence of 10%FBS2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID533692Trough plasma concentration at 12 hrs in HIV-negative human at 400 mg, po administered as single dose followed by 4 days wash out period followed by ritonavir dosing at 100 mg, po bid for 16 days coadministered with compound at 400 mg, po on day 142008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
AID575629Drug level in healthy human urine assessed as raltegravir-glucoronide at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week measured at 0-12 hrs post dose by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID586142Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase V201I mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID587735Antiviral activity against HIV1 NL4-3.Luc assessed as infectivity using human PBMC pretreated for 24 hrs followed by exposed to virus after compound washout measured after 2 to 3 days by luciferase assay2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID586140Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase E157Q mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID1073321Antiviral activity against HIV-1 harboring integrase E138K/Q148K double mutant relative to wild type HIV12014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID541112Cytotoxicity against human MT2 cells infected with HIV1 3B by three fold dilution method in presence of 10% FBS2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1073332Antiviral activity against HIV-1 harboring integrase G140S mutant relative to wild type HIV12014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID508281Antiviral activity against Human immunodeficiency virus 1 clone 2253 harboring integrase S17N, V31I, I72V, L101I, T124A, K156N,V201I, I220M, D279G, R284G mutation transfected into human C8166 cells assessed as decrease in compound susceptibility relative 2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector.
AID1406293Selectivity index, ratio of IC50 for HIV integrase strand transfer activity to IC50 for HIV1 reverse transcriptase RNaseH activity2018European journal of medicinal chemistry, Aug-05, Volume: 1566-Arylthio-3-hydroxypyrimidine-2,4-diones potently inhibited HIV reverse transcriptase-associated RNase H with antiviral activity.
AID582869Antiviral activity against Human immunodeficiency virus 1 clone 16 harboring integrase R20K, A23V, M50I, T124N, G193E, V201I, T206S, I220V, D279G mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID1348217Antiviral activity against wild-type VSV-G pseudotyped HIV1 infected in HEK293 cells assessed as time of 50% failure at 1 uM measured at 48 hrs post infection by luciferase reporter gene assay2017Journal of natural products, 12-22, Volume: 80, Issue:12
Oxazole-Containing Diterpenoids from Cell Cultures of Salvia miltiorrhiza and Their Anti-HIV-1 Activities.
AID1073336Antiviral activity against HIV-1 harboring integrase E92Q mutant relative to wild type HIV12014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID413253Inhibition of HIV1 integrase strand transfer activity2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.
AID582833Intracellular compound distribution in ratio in HIV-infected human PBMC at Cmax by LC-MS/MS analysis2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.
AID364246Antiviral activity against HIV1 with integrase T66I/M154 mutation by single cycle infectivity assay in presence of 10%FBS2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID508289Antiviral activity against Human immunodeficiency virus 1 clone 8070_2 harboring integrase G140S, Q148H, K14R, L63I, L101I, T112A, G193E, D229E, D279G mutation transfected in human C8166 cells assessed as decrease in compound susceptibility relative to wi2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector.
AID575638Ratio of drug level to raltegravir-glucoronide level in healthy human urine at 400 mg, po Bid for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID364192Terminal half life in Sprague-Dawley rat at 3 mg/kg, iv2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID364205Oral bioavailability in po dosed Sprague-Dawley rat2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID562136Tmax in healthy human at 800 mg/kg, po BID for 14 days in presence of 600 mg/kg, po rifampin2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
AID364208Cmax in Sprague-Dawley rat at 3 mg/kg, po2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID1298362Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in gag level at 5 to 200 nM measured at 6 to 12 hrs post infection by qPCR method2016Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11
Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
AID375397Therapeutic index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration of novel thiobarbituric acid-, rhodanine- and thiohydantoin-based HIV-1 integrase inhibitors.
AID584778Drug level in HIV-seronegative healthy volunteers blood at 400 mg, po administered as single dose after 12 hrs by LC-MS/MS2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
AID364202Plasma clearance in dog at 1 mg/kg, iv2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
AID1264512Inhibition of HIV-1 integrase strand transfer activity preincubated for 30 mins followed by addition of FITC-labelled dsDNA for 1 hr by microplate reader analysis2015ACS medicinal chemistry letters, Oct-08, Volume: 6, Issue:10
Design, Synthesis, and Biological Evaluation of 1,2-Dihydroisoquinolines as HIV-1 Integrase Inhibitors.
AID575620Ctau in healthy human plasma assessed as raltegravir-glucoronide at 400 mg, po Bid for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID575639Ratio of drug level to raltegravir-glucoronide level in healthy human urine at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID582871Antiviral activity against Human immunodeficiency virus 1 clone 19 harboring integrase R20K, A23V, G70E, T124N, I141V, G193E, V201I, T206S, I220V mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID586157Antiviral activity against Human immunodeficiency virus 1 clone 19 harboring integrase E11D, S17T, L45V, M50T, I72V, L74I, T97A, K111T, S119G, T125A relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID556546Drug level in patient with severe renal insufficiency assessed as recovery of unchanged drug at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID665832Antiviral activity against HIV infected in human TZM-bl cells at 10 uM after 48 hrs by luciferase-based reporter gene assay2012European journal of medicinal chemistry, Jul, Volume: 53Design, synthesis and antiviral activity of novel quinazolinones.
AID562125Primary phase half life in healthy human at 400 mg/kg, po administered as single dose in presence of 600 mg/kg, po rifampin2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
AID575621Plasma concentration in healthy human assessed as raltegravir-glucoronide at 400 mg, po Bid for 1 week measured 12 hrs post dose by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID533694Primary phase half life in HIV-negative human at 400 mg, po administered as single dose2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
AID1073316Antiviral activity against HIV-1 harboring integrase G140C mutant relative to wild type HIV12014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Inhibiting the HIV integration process: past, present, and the future.
AID533684Cmax in HIV-negative human at 400 mg, po administered as single dose followed by 4 days wash out period followed by efavirenz dosing at 600 mg, po bid for 14 days coadministered with compound at 400 mg, po on day 122008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
AID1597908Chronic cytotoxicity against cat FL-4 cells assessed as decrease in cell viability measured after 7 days by MTT assay2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Novel epidithiodiketopiperazines as anti-viral zinc ejectors of the Feline Immunodeficiency Virus (FIV) nucleocapsid protein as a model for HIV infection.
AID556538Primary phase half life in healthy human at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID586165Antiviral activity against Human immunodeficiency virus 1 clone 10 harboring integrase S17N, I84I, T124N, T125A, M154I, E157K, S195C mutant gene relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID575608Drug level in healthy human urine at 400 mg, po Bid coadministered with atazanavir 400 mg, po qd for 1 week measured at 0-12 hrs post dose by LC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers.
AID586152Antiviral activity against Human immunodeficiency virus 1 clone 8 harboring integrase E11D, S17T, L45V, M50T, S57G, L74I, K111T, S119G, T125A relative to wild type HIV12010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
AID584783AUC (0 to 12 hrs) in HIV-seronegative healthy volunteers at 400 mg, po administered as single dose by LC-MS/MS in presence of albuminium, magnesium and simethicone-containg antacid2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers.
AID541166Selectivity ratio of EC50 for antiviral activity against HIV1 harboring G140S mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID573971Inhibition of Human immunodeficiency virus 1 integrase strand transfer activity2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.
AID760000Cytotoxicity against human MT4 cells by MTT assay2013ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7
4-Substituted 2-Hydroxyisoquinoline-1,3(2H,4H)-diones as a Novel Class of HIV-1 Integrase Inhibitors.
AID556559Toxicity in human assessed as mouth ulceration at 400 mg, po administered as single dose2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1798545Microtiter Plate Assay for Strand Transfer from Article 10.1021/jm800245z: \\Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.\\2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (99)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's16 (16.16)29.6817
2010's68 (68.69)24.3611
2020's15 (15.15)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 69.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index69.00 (24.57)
Research Supply Index4.70 (2.92)
Research Growth Index4.91 (4.65)
Search Engine Demand Index116.42 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (69.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (9.00%)5.53%
Reviews2 (2.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other89 (89.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]